0001213900-20-042808.txt : 20201215 0001213900-20-042808.hdr.sgml : 20201215 20201215170043 ACCESSION NUMBER: 0001213900-20-042808 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20201031 FILED AS OF DATE: 20201215 DATE AS OF CHANGE: 20201215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rafael Holdings, Inc. CENTRAL INDEX KEY: 0001713863 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE [6500] IRS NUMBER: 822296593 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38411 FILM NUMBER: 201390209 BUSINESS ADDRESS: STREET 1: 520 BROAD STREET CITY: NEWARK STATE: NJ ZIP: 07120 BUSINESS PHONE: 973-438-1000 MAIL ADDRESS: STREET 1: 520 BROAD STREET CITY: NEWARK STATE: NJ ZIP: 07120 10-Q 1 f10q1020_rafaelholding.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

for the quarterly period ended October 31, 2020.

☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934.

Commission File Number: 000-55863

RAFAEL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		82-2296593
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

520 Broad Street, Newark, New Jersey 07102

(Address of principal executive offices, zip code)

(212) 658-1450

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Class B common stock, par value $0.01 per share		RFL		New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

The number of shares outstanding of the registrant’s common stock as of December 14, 2020 was:

Class A common stock, par value $0.01 per share:	787,163 shares
Class B common stock, par value $0.01 per share:	15,044,547 shares

RAFAEL HOLDINGS, INC.

TABLE OF CONTENTS

Part I. FINANCIAL INFORMATION

	Item 1.	Financial Statements (Unaudited)	1
		Consolidated Balance Sheets as of October 31, 2020 and July 31, 2020	1
		Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended October 31, 2020 and 2019	2
		Consolidated Statements of Equity for the Three Months Ended October 31, 2020 and 2019	3
		Consolidated Statements of Cash Flows for the Three Months Ended October 31, 2020 and 2019	4
		Notes to Consolidated Financial Statements	5
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
	Item 3.	Quantitative and Qualitative Disclosures about Market Risks	27
	Item 4.	Controls and Procedures	27

Part II. OTHER INFORMATION

	Item 1.	Legal Proceedings	28
	Item 1A.	Risk Factors	28
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
	Item 3.	Defaults Upon Senior Securities	28
	Item 4.	Mine Safety Disclosures	28
	Item 5.	Other Information	28
	Item 6.	Exhibits	29

SIGNATURES			30

PART 1. FINANCIAL INFORMATION

ITEM 1. Financial Statements

RAFAEL HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

(unaudited, in thousands, except share and per share data)

	October 31, 2020			July 31, 2020
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	7,231		$	6,206
Trade accounts receivable, net of allowance for doubtful accounts of $256 and $218 at October 31, 2020 and July 31, 2020, respectively		309			267
Due from Rafael Pharmaceuticals		240			118
Prepaid expenses and other current assets		460			273
Assets held for sale		—			2,968
Total current assets		8,240			9,832

Property and equipment, net		44,141			44,433
Equity investment – RP Finance		288			192
Due from RP Finance LLC		1,875			—
Investments – Rafael Pharmaceuticals		70,018			70,018
Investments – Other Pharmaceuticals		477			1,201
Investments – Hedge Funds		6,454			7,510
Deferred income tax assets, net		—			6
In-process research and development and patents		1,575			1,575
Other assets		1,550			1,580
TOTAL ASSETS	$	134,618		$	136,347
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Trade accounts payable	$	1,155		$	921
Accrued expenses		443			1,191
Amount due for purchase of membership interest		3,500			3,500
Other current liabilities		141			115
Due to related parties		30			—
Total current liabilities		5,269			5,727

Other liabilities		33			92
TOTAL LIABILITIES		5,302			5,819

COMMITMENTS AND CONTINGENCIES

EQUITY
Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of October 31, 2020 and July 31, 2020, respectively		8			8
Class B common stock, $0.01 par value; 200,000,000 shares authorized, 15,050,609 issued and 15,044,547 outstanding as of October 31, 2020, and 15,034,598 issued and 15,028,536 outstanding as of July 31, 2020		149			149
Additional paid-in capital		129,393			129,136
Accumulated deficit		(17,701	)		(16,255	)
Accumulated other comprehensive income related to foreign currency translation adjustment		3,724			3,762
Total equity attributable to Rafael Holdings, Inc.		115,573			116,800
Noncontrolling interests		13,743			13,728
TOTAL EQUITY		129,316			130,528
TOTAL LIABILITIES AND EQUITY	$	134,618		$	136,347

See accompanying notes to consolidated financial statements.

RAFAEL HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited, in thousands, except share and per share data)

	Three Months Ended October 31,
	2020			2019
REVENUE
Rental – Third Party	$	236		$	346
Rental – Related Party		520			520
Parking		177			224
Other – Related Party		120			120
Total revenue		1,053			1,210

COSTS AND EXPENSES
Selling, general and administrative		2,592			2,041
Research and development		515			245
Depreciation and amortization		437			466
Loss from operations		(2,491	)		(1,542	)

Interest expense, net		—			(64	)
Net loss resulting from foreign exchange transactions		—			(5	)
Gain on sale of building		749			—
Impairment of investments - Other Pharmaceuticals		(724	)		—
Unrealized gain (loss) on investments - Hedge Funds		944			(37	)
Loss before income taxes		(1,522	)		(1,648	)
Provision for income taxes		(5	)		(4	)
Equity in earnings of RP Finance		96			—
Consolidated net loss		(1,431	)		(1,652	)
Net loss (income) attributable to noncontrolling interests		15			(54	)
Net loss attributable to Rafael Holdings, Inc.	$	(1,446	)	$	(1,598	)

OTHER COMPREHENSIVE LOSS
Net loss	$	(1,431	)	$	(1,652	)
Foreign currency translation adjustment		(38	)		6
Total comprehensive loss		(1,469	)		(1,646	)
Comprehensive loss attributable to noncontrolling interests		(21	)		(2	)
Total comprehensive loss attributable to Rafael Holdings, Inc.	$	(1,490	)	$	(1,648	)

Loss per share
Basic and diluted	$	(0.09	)	$	(0.10	)

Weighted average number of shares used in calculation of loss per share
Basic and diluted		15,822,722			15,640,683

See accompanying notes to consolidated financial statements.

RAFAEL HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF EQUITY

(unaudited, in thousands, except share and per share data)

	Three Months Ended October 31, 2020
	Common Stock, Series A				Common Stock, Series B				Additional Paid - in		Accumulated			Accumulated other comprehensive			Noncontrolling		Total
	Shares		Amount		Shares		Amount		Capital		Deficit			income			interests		Equity
Balance at July 31, 2020		787,163	$	8		15,028,536	$	149	$	129,136	$	(16,255	)	$	3,762		$	13,728	$	130,528
Net loss for the three months ended October 31, 2020		—		—		—		—		—		(1,446	)		—			15		(1,431	)
Stock-based compensation		—		—		7,261		—		214		—			—			—		214
Stock options exercised		—		—		8,750		—		43		—			—			—		43
Foreign currency translation adjustment		—		—		—		—		—		—			(38	)		—		(38	)
Balance at October 31, 2020		787,163	$	8		15,044,547	$	149	$	129,393	$	(17,701	)	$	3,724		$	13,743	$	129,316

	Three Months Ended October 31, 2019
	Common Stock, Series A				Common Stock, Series B				Additional Paid - in		Accumulated			Accumulated other comprehensive		Noncontrolling			Total
	Shares		Amount		Shares		Amount		Capital		Deficit			income		interests			Equity
Balance at July 31, 2019		787,163	$	8		13,142,502	$	131	$	112,898	$	(5,840	)	$	3,784	$	13,783		$	124,764
Net loss for the three months ended October 31, 2019		—		—		—		—		—		(1,598	)		—		(54	)		(1,652	)
Stock-based compensation		—		—		5,000		—		94		—			—		—			94
Shares issued for convertible note		—		—		1,849,749		18		15,650		—			—		—			15,668
Conversion of LipoMedix bridge notes		—		—		—		—		—		—			—		82			82
Foreign currency translation adjustment		—		—		—		—		—		—			6		—			6
Balance at October 31, 2019		787,163	$	8		14,997,251	$	149	$	128,642	$	(7,438	)	$	3,790	$	13,811		$	138,962

See accompanying notes to consolidated financial statements.

RAFAEL HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

	Three Months Ended October 31,
	2020			2019
Operating activities
Net loss	$	(1,431	)	$	(1,652	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		437			466
Deferred income taxes		6			1
Net unrealized (gain) loss on investments - Hedge Funds		(944	)		37
Impairment of investments - Other Pharmaceuticals		724			—
Equity in earnings of RP Finance		(96	)		—
Provision for doubtful accounts		38			48
Stock-based compensation		214			94
Amortization of debt discount		—			54
Gain on sale of building		(749	)		—

Change in assets and liabilities:
Trade accounts receivable		(80	)		173
Prepaid expenses and other current assets		(187	)		217
Other assets		30			(289	)
Accounts payable and accrued expenses		(490	)		(196	)
Due from Rafael Pharmaceuticals		(122	)		—
Other current liabilities		26			(12	)
Due to related parties		30			(37	)
Due from Rafael Pharmaceuticals		—			160
Other liabilities		(59	)		—
Net cash used in operating activities		(2,653	)		(936	)

Investing activities
Purchases of property and equipment		(145	)		(321	)
Payment to fund RP Finance		(1,875	)		—
Proceeds from sale of building		3,658			—
Proceeds related to distribution of Hedge Funds		2,000			—
Net cash provided by (used in) investing activities		3,638			(321	)

Financing activities
Proceeds from exercise of options		43			—
Net cash provided by financing activities		43			—
Effect of exchange rate changes on cash and cash equivalents		(3	)		4
Net increase (decrease) in cash and cash equivalents		1,025			(1,253	)
Cash and cash equivalents, beginning of period		6,206			12,024
Cash and cash equivalents, end of period	$	7,231		$	10,771

Supplemental schedule of noncash investing and financing activities
Conversion of LipoMedix bridge notes	$	—		$	82
Conversions of related party convertible notes payable and accrued interest	$	—		$	15,668

See accompanying notes to consolidated financial statements.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 – DESCRIPTION OF BUSINESS

Rafael Holdings, Inc. (“Rafael Holdings” or the “Company”), a Delaware corporation, owns interests in pre-clinical and clinical stage pharmaceutical companies and commercial real estate assets. The assets are operated as two separate lines of business.

The pharmaceutical holdings include preferred and common equity interests and a warrant to purchase additional equity interests in Rafael Pharmaceuticals, Inc., or Rafael Pharmaceuticals, which is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells; and, a majority equity interest in LipoMedix Pharmaceuticals Ltd., or LipoMedix, a clinical stage oncological pharmaceutical company based in Israel. In addition, in 2019, we established the Barer Institute (“Barer”), a wholly-owned early stage venture focused on developing a pipeline of therapeutic compounds, including compounds to regulate cancer metabolism. The venture is pursuing collaborative research agreements with leading scientists from top academic institutions to develop other early stage ventures. In addition, we have recently initiated efforts to develop other early stage pharmaceutical ventures.

The commercial real estate holdings consist of a building at 520 Broad Street in Newark, New Jersey that serves as headquarters for the Company and certain other entities and hosts other tenants and an associated 800-car public garage, and a portion of a building in Israel. In August 2020, the Company sold an office/data center building in Piscataway, New Jersey, which was classified as held for sale at July 31, 2020.

The “Company” in these consolidated financial statements refers to Rafael Holdings on a consolidated basis. All significant intercompany accounts and transactions have been eliminated in consolidation.

All majority-owned subsidiaries are consolidated with all intercompany transactions and balances being eliminated in consolidation or combination. The entities included in these consolidated financial statements are as follows:

Company	Country of Incorporation	Percentage Owned
Rafael Holdings, Inc.	United States – Delaware		100	%
Broad Atlantic Associates, LLC	United States – Delaware		100	%
IDT 225 Old NB Road, LLC	United States – Delaware		100	%
IDT R.E. Holdings Ltd.	Israel		100	%
Rafael Holdings Realty, Inc.	United States – Delaware		100	%
Barer Institute, Inc.	United States – Delaware		100	%
The Barer Institute, LLC	United States – Delaware		100	%
Hillview Avenue Realty, JV	United States – Delaware		100	%
Hillview Avenue Realty, LLC	United States – Delaware		100	%
Levco Pharmaceuticals Ltd.	Israel		95	%
Farber Partners, LLC	United States – Delaware		93	%
Pharma Holdings, LLC	United States – Delaware		90	%
LipoMedix Pharmaceuticals Ltd.	Israel		68	%
CS Pharma Holdings, LLC	United States – Delaware		45	%*

50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included.

The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal 2020 refers to the fiscal year ended July 31, 2020).

Operating results for the three months ended October 31, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2021. The balance sheet at July 31, 2020 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2020, or the 2020 Form 10-K, as filed with the U.S. Securities and Exchange Commission (“SEC”).

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates.

Risks and Uncertainties - COVID-19

In December 2019, a new coronavirus, now known as COVID-19, which has proved to be highly contagious, emerged in Wuhan, China and has since spread around the globe. The Company actively monitors the outbreak and its potential impact on its operations and those of the Company’s holdings.

The impacts on the operations and specifically the ongoing clinical trials of our pharmaceutical holdings have been actively managed by respective pharmaceutical management teams who have worked closely with the appropriate regulatory agencies to continue clinical trial activities with as minimal impact as possible from the pandemic, including receiving waivers for certain clinical trial activities from the respective regulatory agencies to continue the studies.

The Company has one tenant that has not paid rent for August 2020 due to the New Jersey state gym closures; however, the tenant subsequently resumed rent payments. There is a general degree of uncertainty in the national commercial real estate market based on the COVID-19 pandemic and as a result there is a potential impact to the value of the Company’s real estate portfolio as well as efforts to monetize those assets.

The Company has implemented a number of measures to protect the health and safety of our workforce including a mandatory work-from-home policy for our workforce who can perform their jobs from home as well as restrictions on business travel and workplace and in-person meetings.

Due to both known and unknown risks, including quarantines, closures and other restrictions resulting from the outbreak, operations and those of the Company’s holdings may be adversely impacted. Additionally, as there is an evolving nature to the COVID-19 situation, we cannot reasonably assess or predict at this time the full extent of the negative impact that the COVID-19 pandemic may have on our business, financial condition, results of operations and cash flows. The impact will depend on future developments such as the ultimate duration and the severity of the spread of the COVID-19 pandemic in the U.S. and globally, the effectiveness of federal, state, local and foreign government actions on mitigation and spread of COVID-19, the pandemic’s impact on the U.S. and global economies, changes in our customers’ behavior emanating from the pandemic and how quickly we can resume our normal operations, among others. For all these reasons, the Company may incur expenses or delays relating to such events outside of the Company’s control, which could have a material adverse impact on the Company’s business.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Investments

The method of accounting applied to long-term investments, whether consolidated, equity or cost, involves an evaluation of the significant terms of each investment that explicitly grant or suggest evidence of control or influence over the operations of the investee and also includes the identification of any variable interests in which the Company is the primary beneficiary. The consolidated financial statements include the Company’s controlled affiliates. All significant intercompany accounts and transactions between the consolidated affiliates are eliminated.

Investments in businesses that the Company does not control, but in which the Company has the ability to exercise significant influence over operating and financial matters, are accounted for using the equity method. Investments in which the Company does not have the ability to exercise significant influence over operating and financial matters are accounted for using the cost method. The Company periodically evaluates its investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded in the accompanying consolidated statements of operations and comprehensive loss, and a new basis in the investment is established.

Variable Interest Entities

In accordance with Accounting Standards Codification (“ASC”) 810, Consolidation, the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities (“VIEs”). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE.

If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary.

Cost Method Investments - Rafael Pharmaceuticals (see Note 3) is a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals’ economic performance. Cost method investments are presented as “Investments - Rafael Pharmaceuticals.”

Equity Method Investments - RP Finance, LLC (“RP Finance”), (see Note 5), has been identified as a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of RP Finance that most significantly impact RP Finance’s economic performance and, therefore, is not required to consolidate RP Finance. The Company accounts for its investment in RP Finance using the equity method of accounting.

Revenue Recognition

The Company applies the five-step approach as described in ASC 606, Revenue from Contracts with Customers, which consists of the following: (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations in the contract and (v) recognizing revenue when (or as) the entity satisfies a performance obligation.

The Company disaggregates its revenue by source within its consolidated statements of operations and comprehensive loss. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing office and parking space to tenants at its properties. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recorded together with rental income on the consolidated statements of operations and comprehensive loss which is also consistent with the guidance under ASC 842, Leases.

Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within other assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements.

The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company’s performance obligation is satisfied, consistent with the Company’s previous accounting.

The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Research and Development Costs

Research and development costs and expenses incurred by consolidated entities consist primarily of salaries and related personnel expenses, stock-based compensation, fees paid to external service providers, laboratory supplies, costs for facilities and equipment, license costs, and other costs for research and development activities. Research and development expenses are recorded in operating expenses in the period in which they are incurred. Estimates have been used in determining the liability for certain costs where services have been performed but not yet invoiced. The Company monitors levels of performance under each significant contract for external service providers, including the extent of patient enrollment and other activities through communications with the service providers to reflect the actual amount expended.

Contingent milestone payments associated with acquiring rights to intellectual property are recognized when probable and estimable. These amounts are expensed to research and development when there is no alternative future use associated with the intellectual property.

Recently Issued Accounting Standards Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, that changes the impairment model for most financial assets and certain other instruments. For receivables, loans and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowance for losses. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to current practice, except the losses will be recognized as allowances instead of reductions in the amortized cost of the securities. In addition, an entity will have to disclose significantly more information about allowances, credit quality indicators and past due securities. The new standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and will be applied as a cumulative-effect adjustment to retained earnings. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and intends to adopt the standard on August 1, 2023.

NOTE 3 – INVESTMENT IN RAFAEL PHARMACEUTICALS

Rafael Pharmaceuticals is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.

The Company owns equity interests and rights in Rafael Pharmaceuticals through a 90%-owned non-operating subsidiary, Pharma Holdings, LLC, or Pharma Holdings.

Pharma Holdings owns 50% of CS Pharma Holdings, LLC, or CS Pharma, a non-operating entity that owns equity interests in Rafael Pharmaceuticals. Accordingly, the Company holds an effective 45% indirect interest in the assets held by CS Pharma.

Howard Jonas, Chairman of the Board and Chief Executive Officer of the Company, and Chairman of the Board of Rafael Pharmaceuticals, owns 10% of Pharma Holdings.

Pharma Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase ownership to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments, and will expire upon the earlier of June 30, 2021, a qualified initial public offering, or liquidation event of Rafael Pharmaceuticals.

On March 25, 2020, the Board of Directors of Rafael Pharmaceuticals extended the expiration date of the Warrant held by Pharma Holdings to purchase shares of the Warrant from December 31, 2020 to June 30, 2021 and on August 31, 2020 the Board of Directors of Rafael Pharmaceuticals further extended the expiration date of the Warrant held by Pharma Holdings, LLC to purchase shares of the Warrant to August 15, 2021.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Pharma Holdings also holds certain governance rights in Rafael Pharmaceuticals including appointment of directors.

CS Pharma holds 16.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock. CS Pharma owned a $10 million Series D Convertible Note, with 3.5% interest, in Rafael Pharmaceuticals which was converted in January 2019.

The Company and its subsidiaries collectively own securities representing 51% of the outstanding capital stock of Rafael Pharmaceuticals and 37% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant).

The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution or winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class.

The Company serves as the managing member of Pharma Holdings, and Pharma Holdings serves as the managing member of CS Pharma, with broad authority to make all key decisions regarding their respective holdings. Any distributions that are made to CS Pharma from Rafael Pharmaceuticals that are in turn distributed by CS Pharma, will need to be made pro rata to all members, which would entitle Pharma Holdings to 50% (based on current ownership) of such distributions. Similarly, if Pharma Holdings were to distribute proceeds it receives from CS Pharma, it would do so on a pro rata basis, entitling the Company to 90% (based on current ownership) of such distributions.

The Company evaluated its investments in Rafael Pharmaceuticals in accordance with ASC 323, Investments - Equity Method and Joint Ventures, to establish the appropriate accounting treatment for its investment and has concluded that its investment did not meet the criteria for the equity method of accounting or consolidation and is carried at cost.

Rafael Pharmaceuticals is a VIE; however, the Company has determined that it is not the primary beneficiary as it does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals’ economic performance. In addition, the interests held in Rafael Pharmaceuticals are Series D Convertible Preferred Stock and do not represent in-substance common stock.

Howard Jonas has additional contractual rights to receive additional Rafael Pharmaceuticals shares (“Bonus Shares”) for an additional 10% of the fully diluted capital stock of Rafael Pharmaceuticals upon the achievement of certain milestones. The additional 10% is based on the fully diluted capital stock of Rafael Pharmaceuticals, excluding the remainder for the Warrant, at the time of issuance. If any of the milestones are met, the Bonus Shares are to be issued without any additional payment. Howard Jonas has the right to transfer the Bonus Shares, in his discretion, to others, including those who are instrumental to the future success of Rafael Pharmaceuticals.

The Company holds a Warrant to purchase a significant stake in Rafael Pharmaceuticals, as well as other equity and governance rights in Rafael Pharmaceuticals. As of October 31, 2020, the Company owned 51% of the issued and outstanding equity in Rafael Pharmaceuticals. At that date, approximately 8% of the issued and outstanding equity was owned by the Company’s subsidiary CS Pharma and 42% was held by the Company’s subsidiary Pharma Holdings. The Company’s subsidiary Pharma Holdings holds a non-dilutive option to increase the Company’s total ownership to 56%. Based on the shares issued and outstanding of Rafael Pharmaceuticals as of October 31, 2020, the Company, and the Company’s affiliates, would need to pay approximately $16 million to exercise the Warrant in full. On an as-converted fully diluted basis (for all convertible securities of Rafael Pharmaceuticals outstanding), the Company, and the Company’s affiliates would need to pay approximately $104 million to exercise the Warrant in full. including additional issuances under the Line of Credit. Howard Jonas holds 10% of the interest in Pharma Holdings and would need to contribute 10% of any cash necessary to exercise any additional portion of the Warrant. Following any exercise, a portion of the Company’s interest in Rafael Pharmaceuticals would continue to be held for the benefit of the other equity holders in Pharma Holdings and CS Pharma. Given the Company’s anticipated available cash, the Company would not be able to exercise the Warrant in its entirety and the Company may never be able to exercise the Warrant in full. Rafael Pharmaceuticals may also issue additional equity interests, such as stock options, which will require the Company to pay additional cash to maintain the Company’s ownership percentage or exercise the Warrant in full.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 4 – INVESTMENT IN ALTIRA

The Company entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) on May 13, 2020 with a member (the “Seller”) of Altira Capital & Consulting, LLC (“Altira”). Pursuant to the Purchase Agreement, on May 13, 2020, the Seller sold the economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive a 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceutical) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the membership interest consists of 1) $1,000,000 payable monthly in four equal installments of $250,000 each; 2) $3,000,000 due on January 3, 2021; 3) $3,000,000 due within fifteen (15) days of interim data analysis in Rafael Pharmaceuticals’ Phase 3 pivotal trial (AVENGER 500®) of CPI-613® (devimistat); and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement. The post-closing payments are to be made, at the Company’s discretion, in cash or shares of the Company’s Class B common stock based on the ten days average share price of the Company’s Class B common stock prior to the date of payment or any combination thereof.

The Company has accounted for the purchase of the 33.333% membership interest in Altira as an equity method investment in accordance with the guidance in ASC 323, Investments – Equity Method and Joint Ventures. The Company determined that a 33.333% membership interest in Altira indicates that the Company is able to exercise significant influence over Altira, and the Company’s membership interest is considered to be “more than minor” in accordance with the guidance. The cost of the investment was determined to be $4,000,000 pursuant to the terms of the Purchase Agreement. The contingent consideration, as described within the Purchase Agreement, in the amount of $6,000,000, will be recognized when the payments are considered probable.

For the year ended July 31, 2020, the Company determined that the investment in Altira was fully impaired and recorded an impairment charge of $4,000,000, which was the total amount of the investment in Altira.

During the three months ended October 31, 2020, the Company did not make any payments to the Seller, and the remaining payments due to the Seller of $3,500,000 are recorded as a current liability. The assets and operations of Altira are not significant, and the Company has identified the equity investment in Altira as a related party transaction (see Note 11).

NOTE 5 – INVESTMENT IN RP FINANCE, LLC

On February 3, 2020, Rafael Pharmaceuticals entered into a Line of Credit Loan Agreement (“Line of Credit Agreement”) with RP Finance which provides a revolving commitment of up to $50,000,000 to fund clinical trials and other capital needs.

The Company owns 37.5% of the equity interests in RP Finance and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. Howard Jonas owns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. The remaining 25% equity interests in RP Finance is owned by other shareholders of Rafael Pharmaceuticals.

Under the Line of Credit Agreement, all funds borrowed will bear interest at the mid-term Applicable Federal Rate published by the U.S. Internal Revenue Service. The maturity date is the earlier of February 3, 2025, upon a change of control of Rafael Pharmaceuticals or a sale of Rafael Pharmaceuticals or its assets. Rafael Pharmaceuticals can draw on the facility on 60 days’ notice. The funds borrowed under the Line of Credit Agreement must be repaid out of certain proceeds from equity sales by Rafael Pharmaceuticals.

In connection with entering into the Line of Credit Agreement, Rafael Pharmaceuticals agreed to issue to RP Finance shares of its common stock representing 12% of the issued and outstanding shares of Rafael Pharmaceuticals common stock, with such interest subject to anti-dilution protection as set forth in the Line of Credit Agreement.

RP Finance has been identified as a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of RP Finance that most significantly impact RP Finance’s economic performance and, therefore, is not required to consolidate RP Finance. Therefore, we will use the equity method of accounting to record our investment in RP Finance. The Company has recognized approximately $96 thousand and $0 in income from its ownership interests of 37.5% in RP Finance for the three months ended October 31, 2020 and 2019, respectively. The assets and operations of RP Finance are not significant and the Company has identified the equity investment in RP Finance as a related party transaction (see Note 11).

In August 2020, Rafael Pharmaceuticals called for a $5,000,000 draw on the line of credit facility and the facility was funded by RP Finance LLC in the amount $5 million, in August 2020 and September 2020. For the three months ended October 31, 2020, the Company funded $1,875,000 in accordance with its 37.5% ownership interests in RP Finance.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 6 – INVESTMENT IN LIPOMEDIX PHARMACEUTICALS LTD.

LipoMedix is a development-stage, privately held Israeli company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery.

As of October 31, 2020, the Company held 68% of the issued and outstanding ordinary shares of LipoMedix and has consolidated this investment from the second quarter of fiscal 2018.

In November 2019, the Company provided bridge financing in the principal amount of $100,000 to LipoMedix with a maturity date of May 3, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets.

In January 2020, the Company provided bridge financing in the principal amount of $125,000 to LipoMedix with a maturity date of May 3, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets.

In March 2020, the Company provided bridge financing in the principal amount of $75,000 to LipoMedix with a maturity date of April 20, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets.

On May 20, 2020, the Company entered into a Share Purchase Agreement with LipoMedix to purchase 4,000,000 ordinary shares of LipoMedix for an aggregate purchase price of $1,000,000. The purchase consideration consisted of the outstanding Promissory Notes between the Company and LipoMedix dated November 13, 2019, January 21, 2020 and March 27, 2020 in the total principal amount of $300,000 plus accrued interest, for an aggregate amount of $306,737, and $693,263 of cash, thereby increasing the Company’s ownership in Lipomedix from 58% to 68%.

NOTE 7 – FAIR VALUE MEASUREMENTS

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:

●

Level 1 - quoted prices in active markets for identical assets or liabilities;

●

Level 2 - quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or

●

Level 3 - unobservable inputs for the asset or liability, such as discounted cash flow models or valuations.

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The following is a listing of the Company’s assets required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of October 31, 2020 and July 31, 2020:

	Fair value at October 31, 2020
	Level 1		Level 2		Level 3		Total
	*(unaudited, in thousands)*
Assets:
Hedge Funds	$	—	$	—	$	6,454	$	6,454
Total	$	—	$	—	$	6,454	$	6,454

	Fair value at July 31, 2020
	Level 1		Level 2		Level 3		Total
	*(in thousands)*
Assets:
Hedge Funds	$	—	$	—	$	7,510	$	7,510
Total	$	—	$	—	$	7,510	$	7,510

At October 31, 2020 and July 31, 2020, the Company did not have any liabilities measured at fair value on a recurring basis.

The following table summarizes the changes in the fair value of the assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3):

	October 31, 2020			October 31, 2019
	*(unaudited, in thousands)*
Balance, beginning of period	$	7,510		$	5,125
Liquidation of Hedge Fund Investments		(2,000	)		—
Total gain (loss) included in earnings		944			(37	)
Balance, end of period	$	6,454		$	5,088

Hedge funds classified as Level 3 include investments and securities which may not be based on readily observable data inputs. The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. The fair value of these assets is estimated based on information provided by the fund managers or the general partners. Therefore, these assets are classified as Level 3. In October 2020, the Company received a $2 million distribution of the Company’s investments in Hedge Funds.

The Company holds $2.0 million in investments in securities in another entity that are not liquid, which were included in Investments - Other Pharmaceuticals in the accompanying consolidated balance sheets. The investment is accounted for under ASC 321, Investments - Equity Securities, using the measurement alternative as defined within the guidance, and the Company recorded an impairment loss of $0.7 million and $0 for the three months ended October 31, 2020 and 2019, respectively.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Fair Value of Other Financial Instruments

The estimated fair value of the Company’s other financial instruments was determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting these data to develop estimates of fair value. Consequently, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange.

Cash and cash equivalents, prepaid expense and other current assets, and accounts payable. At October 31, 2020 and July 31, 2020, the carrying amount of these assets and liabilities approximated fair value because of the short period of time to maturity. The fair value estimates for cash and cash equivalents were classified as Level 1 and other current assets, and other current liabilities were classified as Level 2 of the fair value hierarchy.

Other assets and other liabilities. At October 31, 2020 and July 31, 2020, the carrying amount of these assets and liabilities approximated fair value. The fair values were estimated based on the Company’s assumptions, which were classified as Level 3 of the fair value hierarchy.

The Company’s financial instruments include trade accounts receivable, trade accounts payable, and due from related parties. The recorded carrying amounts of trade accounts receivable, trade accounts payable and due from related parties approximate their fair value due to their short-term nature. Other than noted above, the Company did not have any other assets or liabilities that were measured at fair value on a recurring basis as of October 31, 2020 or July 31, 2020.

NOTE 8 – TRADE ACCOUNTS RECEIVABLE

Trade Accounts Receivable consisted of the following:

	October 31, 2020			July 31, 2020
	*(unaudited, in thousands)*			*(in thousands)*
Trade Accounts Receivable	$	415		$	364
Accounts Receivable - Related Party		150			121
Less Allowance for Doubtful Accounts		(256	)		(218	)
Trade Accounts Receivable, net	$	309		$	267

The current portion of deferred rental income included in prepaid expenses and other current assets was approximately $77 thousand and $11 thousand as of October 31, 2020 and July 31, 2020, respectively.

The noncurrent portion of deferred rental income included in Other Assets was approximately $1.5 million as of October 31, 2020 and July 31, 2020.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 9 – PROPERTY AND EQUIPMENT

Property and equipment consisted of the following:

	October 31, 2020			July 31, 2020
	*(unaudited, in thousands)*			*(in thousands)*
Building and Improvements	$	47,736		$	47,591
Land		10,412			10,412
Furniture and Fixtures		1,145			1,145
Other		256			256
		59,549			59,404
Less Accumulated Depreciation		(15,408	)		(14,971	)
Total	$	44,141		$	44,433

Other property and equipment consist of other equipment and miscellaneous computer hardware.

Depreciation expense pertaining to property and equipment was approximately $0.4 million and $0.5 million for the three months ended October 31, 2020 and 2019, respectively.

The Company’s headquarters are located at 520 Broad Street in Newark, New Jersey where it occupies office space in the building owned by its subsidiary.

In August 2020, the Company sold an office/data center building in Piscataway, New Jersey, which was classified as held for sale at July 31, 2020.

NOTE 10 – LOSS PER SHARE

Basic net loss per share is computed by dividing net loss attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted loss per shares includes potentially dilutive securities such as stock options and other convertible instruments. These securities have been excluded from the calculation of diluted net loss per shares for the three months ended October 31, 2020 and 2019 because all such securities are anti-dilutive for all periods presented.

The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

	Three months ended October 31,
	2020		2019
Stock Options		571,800		586,874
Total		571,800		586,874

The diluted loss per share computation equals basic loss per share for the three months ended October 31, 2020 and 2019 because the Company had a net loss and the impact of the assumed exercise of stock options would have been anti-dilutive.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 11 – RELATED PARTY TRANSACTIONS

The Company has historically maintained an intercompany balance due to/from related parties that relates to cash advances for investments, loan repayments, charges for services provided to the Company by IDT Corporation, or IDT, and payroll costs for the Company’s personnel that were paid by IDT. The Company also receives rental income from various companies under common control to IDT. The Company recorded expense of approximately $66 thousand in related party services to IDT, of which approximately $30 thousand is included in due to related parties at October 31, 2020.

IDT leases approximately 80,000 square feet of office space plus parking occupied by IDT at 520 Broad Street, Newark, NJ and approximately 3,600 square feet of office space in Jerusalem, Israel. IDT paid the Company approximately $459 thousand for office rent and parking during the three months ended October 31, 2020 and 2019. As of October 31, 2020 and 2019, IDT owed the Company approximately $69 thousand and $0, respectively, for office rent and parking.

The Company leases space to related parties which represented approximately 56% and 43% of the Company’s total revenue for the three months ended October 31, 2020 and 2019, respectively. See Note 16 for future minimum rent payments from related parties and other tenants.

The Company provides Rafael Pharmaceuticals with administrative, finance, accounting, tax and legal services. Howard S. Jonas serves as a Chairman of the Board of Rafael Pharmaceuticals and owns an equity interest in Rafael Pharmaceuticals. The Company billed Rafael Pharmaceuticals $120,000 for the three months ended October 31, 2020 and 2019, respectively. As of October 31, 2020 and July 31, 2020, Rafael Pharmaceuticals owed the Company $240,000 and $120,000, respectively, included in due from Rafael Pharmaceuticals.

In September 2018, CS Pharma, in which the Company owns an effective 45% interest, exercised a warrant to purchase 8 million shares of Rafael Pharmaceuticals’ Series D Convertible Preferred Stock for $10 million representing approximately 8% of the equity on a fully-diluted basis (excluding the remainder of the Warrant) of Rafael Pharmaceuticals. The Warrant in full is exercisable for up to 56% of the fully diluted equity of Rafael Pharmaceuticals. The right to exercise the first $10 million of the Warrant was held by CS Pharma. CS Pharma is owned by 0.25% by Michael Weiss, a non-employee director of the Company. The remainder of the Warrant is held by Pharma Holdings.

On November 5, 2018, Pharma Holdings, LLC partially exercised a warrant to purchase 4 million shares of Rafael Pharmaceuticals’ Series D Convertible Preferred Stock for $5 million, of which $500,000 was contributed by Howard Jonas.

On November 15, 2018, Howard Jonas entered into an agreement to purchase a convertible note from the Company for $15.0 million convertible into shares of Class B common stock at $8.47 per share. The term of the note was three years with interest on the principal amount at a rate of 6% per annum, compounded quarterly. At issuance, the Company recorded a debt discount of approximately $70,000 related to the beneficial conversion feature of the note and amortized approximately $16,000 of the discount in fiscal 2020 which was recorded as interest expense. In addition, the Company recorded approximately $650,000 of interest expense for the three months ended October 31, 2020 and 2019. In August 2019, the note including accrued interest of approximately $667,000 was converted into 1,849,749 shares of common stock.

On January 10, 2019, Pharma Holdings partially exercised a warrant to purchase 5.1 million shares of Series D Convertible Preferred Stock of Rafael Pharmaceuticals for $6.4 million, of which $640,000 was contributed by Howard Jonas.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

On January 23, 2019, Pharma Holdings partially exercised a warrant to purchase 36.3 million shares of Series D Convertible Preferred Stock of Rafael Pharmaceuticals for $34.4 million, of which $3.4 million was contributed by Howard Jonas.

On January 29, 2020, in connection with the vesting of certain restricted shares of Class B common stock held by an officer of the Company, the Company withheld 5,238 shares to pay for the payroll taxes on the officer’s behalf, totaling approximately $116,000.

The Company acquired membership interest in Altira, a related party in fiscal 2020 and fiscal 2021 (see Note 4 and Note 17).

The Company recognized approximately $96 thousand and $0 in income from its ownership interests of 37.5% in RP Finance for the three months ended October 31, 2020 and 2019, respectively (see Note 5).

NOTE 12 – INCOME TAXES

The Company has completed its accounting for the income tax effects of the enactment of the Tax Act and Care Act. At October 31, 2020, the Company has federal net operating loss (“NOL”) carryforwards from domestic operations of approximately $34.4 million, to offset future taxable income. The Company has state NOLs of $15.3 million. The Company has NOLs from foreign operations of $2.3 million. As part of the Tax Act, federal NOLs generated in 2018 and later are not subject to an expiration period and are available to offset 80% of taxable income in the year in which they are utilized. The federal NOL carryforwards generated prior to 2018 will begin to expire in 2026. The state NOLs will begin to expire in 2038 and foreign NOLs do not expire.

The Company anticipates that its assumptions and estimates may change as a result of future guidance and interpretation from the Internal Revenue Service, the SEC, the FASB, and various other taxing jurisdictions. In particular, the Company anticipates that the U.S. state jurisdictions will continue to determine and announce their conformity with or decoupling from the Tax Act, either in its entirety or with respect to specific provisions. Legislative and interpretive actions could result in adjustments to the Company’s balances.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 13 – BUSINESS SEGMENT INFORMATION

The Company conducts business as two operating segments, Pharmaceuticals and Real Estate. The Company’s reportable segments are distinguished by types of service, customers and methods used to provide their services. The operating results of these business segments are regularly reviewed by the Company’s CEO and chief operating decision-maker.

The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Pharmaceuticals segment based primarily on research and development efforts and results of clinical trials and the Real Estate segment based primarily on results of operations. All investments in Rafael Pharmaceuticals and assets and expenses associated with LipoMedix and Barer are tracked separately in the Pharmaceuticals segment. All corporate costs are allocated to the Real Estate segment.

The Pharmaceuticals segment is comprised of preferred and common equity interests and the Warrant to purchase equity interests in Rafael Pharmaceuticals, a majority equity interest in LipoMedix and Barer. To date, the Pharmaceuticals segment has not generated any revenues.

The Real Estate segment consists of the Company’s real estate holdings, including a building at 520 Broad Street in Newark, New Jersey that houses headquarters for the Company and certain affiliates and its associated public garage and a portion of an office building in Israel.

In August 2020, the Company sold a 3-story, 65,253 square foot office building located at 225 Old New Brunswick Road in Piscataway, New Jersey to 225 ONBR, LLC, an entity unaffiliated with the Company. The purchase price was $3,875,000 and, after transfer taxes and broker’s commission, the Company received $3,675,638 in cash. As of July 31, 2020, the building was classified as held for sale on the consolidated balance sheet.

Operating results for the business segments of the Company are as follows:

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Three Months Ended October 31, 2020
Revenues	$	—		$	1,053		$	1,053
Loss from operations		(533	)		(1,958	)		(2,491	)

Three Months Ended October 31, 2019
Revenues	$	—		$	1,210		$	1,210
Loss from operations		(266	)		(1,276	)		(1,542	)

Geographic Information

Revenues from tenants located outside of the United States were generated entirely from related parties located in Israel. Revenues from these non-United States customers as a percentage of total revenues were as follows (revenues by country are determined based on the location of the related facility):

Three Months Ended October 31, (unaudited)		2020				2019
Revenue from tenants located in Israel			6	%			5	%

Net long-lived assets and total assets held outside of the United States, which are located in Israel, were as follows:

(unaudited, in thousands)	United States		Israel		Total
October 31, 2020
Long-lived assets, net	$	42,564	$	1,577	$	44,141
Total assets		130,744		3,874		134,618

July 31, 2020
Long-lived assets, net	$	42,840	$	1,593	$	44,433
Total assets		132,286		4,061		136,347

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 14 – COMMITMENTS AND CONTINGENCIES

Legal Proceedings

On September 17, 2018, LipoMedix was notified of a claim initiated by one of its founders seeking payment of consulting fees in the amount of approximately $377,000 and seeking to place restrictions on LipoMedix’s bank accounts and other assets to protect his claim. LipoMedix did not believe that the individual had the right to receive any payment at that time. LipoMedix responded to the demand for the placement of restrictions on its assets. In May 2019, LipoMedix received a letter from the other founder requesting payment of his consulting fees. On July 15, 2019, the parties settled the matters and the two founders will be paid a percentage of future investments and certain other proceeds.

On July 12, 2019, the Company received a Citation and Notification of Penalty from the Occupational Safety and Health Administration of the U.S. Department of Labor, or OSHA, related to an OSHA inspection of 520 Broad Street, Newark, New Jersey. The citation seeks to impose penalties related to alleged violations of the Occupation Safety and Health Act of 1970 at 520 Broad Street. On July 31, 2019, the Company filed a Notice of Contest with OSHA contesting the citation in its entirety. On February 14, 2020, the Company entered into a Settlement Agreement with OSHA, as related to the citation received on July 12, 2019. As part of the Settlement Agreement, the Company agreed to pay a penalty of $127,294 in eight quarterly installment payments through November 2021.

The Company accounts for contingencies when a loss is considered probable and can be reasonably estimated. For the matters disclosed above, a legal accrual for approximately $64,000 has been recorded for legal fees and losses believed to be both probable and reasonably estimable, but an exposure to additional loss may exist in excess of the amount accrued.

On December 31, 2019, an employee of the Company filed a complaint in connection with the incident that led to the OSHA inspection noted above for personal injuries against the Company and other parties in the New Jersey Supreme Court for an incident that took place on January 31, 2019 at 520 Broad Street, Newark, New Jersey. The Company intends to vigorously defend this matter. The loss is considered remote and no accrual has been recorded.

The Company may from time to time be subject to legal proceedings that may arise in the ordinary course of business. Although there can be no assurance in this regard, other than noted above, the Company does not expect any of those legal proceedings to have a material adverse effect on the Company’s results of operations, cash flows or financial condition.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 15 – EQUITY

On November 15, 2018, Howard Jonas entered into an agreement to purchase a convertible note from the Company for $15.0 million that was convertible into shares of Class B common stock at $8.47 per share. The term of the note was three years with interest on the principal amount at a rate of 6% per annum, compounded quarterly.

In August 2019, the note, including interest of approximately $667,000 was converted into 1,849,749 shares of Class B common stock.

Pursuant to the Company’s 2018 Equity Incentive Plan, each of our three non-employee directors of the Company was granted 4,203 restricted shares of our Class B common stock in January 2020 which fully vested on the date of the grant. The fair value of the awards on the date of the grant was approximately $208,000 which was included in selling, general and administrative expense.

During the three months ended October 31, 2020, 8,750 options were exercised. At October 31, 2020, there was no unrecognized compensation cost related to non-vested stock options.

Stock Options

A summary of stock option activity for the Company is as follows:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at July 31, 2020		580,874		$	4.90		2.65	$	2,846
Granted		—			—
Exercised		(8,750	)		4.90
Cancelled / Forfeited		(324	)		—
Outstanding at October 31, 2020		571,800		$	4.90		2.40	$	2,802
Exercisable at October 31, 2020		571,800		$	4.90		2.40	$	2,802

Restricted Stock

The fair value of restricted shares of the Company’s Class B common stock is determined based on the closing price of the Company’s Class B common stock on the grant date. Share awards generally vest on a graded basis over three years of service.

A summary of the status of the Company’s grants of restricted shares of Class B common stock is presented below:

	Number of Non-vested Shares			Weighted Average Grant Date Fair Value
Outstanding at July 31, 2020		123,104		$	10.80
Granted		9,360			16.58
Vested		(7,027	)		(16.91	)
Cancelled / Forfeited		(2,099	)		(13.54	)
Non-vested shares at October 31, 2020		123,338		$	13.79

At October 31, 2020, there was $1.4 million of total unrecognized compensation cost related to non-vested stock-based compensation arrangements, which is expected to be recognized over the next 2.18 years.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 16 – LEASES

The Company is the lessor of certain properties which are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2029. Lease income included on the consolidated statements of operations and comprehensive loss for the three months ended October 31, 2020 and 2019 was $634 thousand and $866 thousand, respectively.

The future contractual minimum lease payments to be received (excluding operating expense reimbursements) by the Company as of October 31, 2020, under non-cancellable operating leases which expire on various dates through 2028 are as follows:

Year ending July 31,	Related Parties		Other		Total
	*(in thousands)*
2021 (remaining)	$	1,532	$	603	$	2,135
2022		2,078		776		2,854
2023		2,117		592		2,709
2024		2,155		538		2,693
2025		1,659		550		2,209
Thereafter		—		1,948		1,948
Total Minimum Future Rental Income	$	9,541	$	5,007	$	14,548

The Company has related party leases that expire in April 2025 for (i) an aggregate of 88,631 square feet, which includes two parking spots per thousand square feet of space leased at 520 Broad Street, Newark, New Jersey, and (ii) 3,595 square feet in Israel. The annual rent is approximately $2.0 million in the aggregate. The related parties have the right to terminate the domestic leases upon four months’ notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months’ notice. IDT has the right to lease an additional 50,000 square feet, in 25,000-foot increments, in the building located at 520 Broad Street, Newark, New Jersey on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.

RAFAEL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 17 – SUBSEQUENT EVENTS

The Company entered into a Membership Interest Purchase Agreement (the “Second Altira Agreement”) on December 7, 2020 with a member (the “Seller”) of Altira. Pursuant to the Second Altira Agreement, on December 7, 2020, the Seller sold the economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive a 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceuticals) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the membership interest consists of 1) $1,000,000 payable monthly in four equal installments of $250,000 each, commencing on January 4, 2021; 2) $3,000,000 due on January 4, 2021; 3) $3,000,000 due within fifteen (15) days of the earlier to occur of either the completion of Rafael Pharmaceuticals’ Phase III pivotal trial (AVENGER 500®) of CPI-613® (devimistat) or May 31, 2021 and not before January 4, 2021; and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement. Certain of the post-closing payments may be made, at the Company’s discretion, in cash or shares of the Company’s Class B common stock based on the ten day average share price of the Company’s Class B common stock prior to the date of payment or any combination thereof.

On December 7, 2020, Rafael Holdings entered into a Securities Purchase Agreement (the “SPA”) for the sale of 567,437 shares of the Company’s Class B common stock at a price per share of $22.91 (which was the closing price for the Class B common stock on the New York Stock Exchange on December 4, 2020 the trading day immediately preceding the date of the SPA) for an aggregate purchase price of $13 million. In connection with the purchases, each purchaser was granted warrants to purchase twenty percent (20%) of the shares of Class B common stock purchased by such purchaser. The warrants have an exercise price of $22.91 per share and expire on June 6, 2022. The Company issued warrants to purchase an aggregate of 113,487 shares of Class B common stock. A majority of the proceeds received pursuant to the SPA are expected to be used by the Company to exercise an additional portion of the warrant held by the Company’s subsidiary to purchase equity securities of Rafael Pharmaceuticals, Inc. in order to maintain the Company’s relative position as a percentage of shares outstanding as well as the fully-diluted equity of Rafael Pharmaceuticals in light of issuances of Rafael Pharmaceuticals equity securities to third-party shareholders of Rafael Pharmaceuticals, including due to warrant exercises by these shareholders. The Company intends to use additional proceeds to fund the operations of its drug development programs including its Barer Institute subsidiary, and for general corporate purposes. Under the SPA, two entities, on whose Boards of Directors Howard Jonas, the Registrant’s Chief Executive Officer and Chairman of the Board serves, each purchased 218,245 shares of Class B common stock for consideration of $10 million. The shares and warrants were issued in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended.

On December 10, 2020, a controlled subsidiary of the Company, Farber Partners LLC, or Farber, reached an agreement with Princeton University to in-license certain patents and related information related to the serine hydroxymethyltransferase (SHMT) inhibitor program developed by the laboratory of Dr. Joshua D. Rabinowitz at Princeton. Farber will pay Princeton a minimum annual royalty payment of $50 thousand, in addition to percentage royalties and a percentage of any sublicense revenue. Additionally, there are development milestone payments which Farber will pay Princeton for the first three products developed by Farber, or any sublicensees or affiliates.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Rafael Holdings, Inc., (“Rafael Holdings” or the “Company”), a Delaware corporation, owns interests in pre-clinical and clinical stage pharmaceutical companies and commercial real estate assets. The assets are operated as two separate lines of business.

The pharmaceutical holdings include preferred and common equity interests and a warrant to purchase additional equity interests in Rafael Pharmaceuticals, Inc., or Rafael Pharmaceuticals, which is a clinical stage, oncology-focused, pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells, and a majority equity interest in LipoMedix Pharmaceuticals Ltd., or LipoMedix, a clinical stage oncological pharmaceutical company based in Israel. In addition, in 2019, we established the Barer Institute (“Barer”), a wholly-owned early stage venture focused on developing a pipeline of therapeutic compounds, including compounds to regulate cancer metabolism. The venture is pursuing collaborative research agreements with leading scientists from top academic institutions. In addition, we have recently initiated efforts to develop other early stage pharmaceutical ventures.

Business Update - COVID-19

In December 2019, a new coronavirus, now known as COVID-19, which has proved to be highly contagious, emerged in Wuhan, China and since has spread around the globe. We actively monitor the outbreak and its potential impact on our operations and those of our holdings.

We have one tenant that has not paid rent for August 2020 due to the New Jersey state gym closures; however, the tenant subsequently resumed rent payments. There is a general degree of uncertainty in the national commercial real estate market based on the COVID-19 pandemic and as a result there is a potential impact to the value of our real estate portfolio as well as efforts to monetize those assets.

We have implemented a number of measures to protect the health and safety of our workforce including a mandatory work-from-home policy for our workforce who can perform their jobs from home as well as restrictions on business travel and workplace and in-person meetings.

Due to both known and unknown risks, including quarantines, closures and other restrictions resulting from the outbreak, operations and those of our holdings may be adversely impacted. Additionally, as there is an evolving nature to the COVID-19 situation, we cannot reasonably assess or predict at this time the full extent of the negative impact that the COVID-19 pandemic may have on our business, financial condition, results of operations and cash flows. The impact will depend on future developments such as the ultimate duration and the severity of the spread of the COVID-19 pandemic in the U.S. and globally, the effectiveness of federal, state, local and foreign government actions on mitigation and spread of COVID-19, the pandemic’s impact on the U.S. and global economies, changes in our customers’ behavior emanating from the pandemic and how quickly we can resume our normal operations, among others. For all these reasons, we may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business.

Results of Operations

Our business consists of two reportable segments - Pharmaceuticals and Real Estate. We evaluate the performance of our Pharmaceuticals segment based primarily on research and development efforts and results of clinical trials and our Real Estate segment based primarily on results of operations. Accordingly, the income and expense line items below loss from operations are only included in the discussion of consolidated results of operations.

Three Months Ended October 31, 2020 Compared to Three Months Ended October 31, 2019

Pharmaceuticals Segment

Our consolidated expenses for our Pharmaceuticals segment were as follows:

	Three Months Ended October 31,						Change
	2020			2019			$			%
	*(unaudited, in thousands)*
Selling, general and administrative	$	(18	)	$	(21	)	$	3			(14	)%
Research and development		(515	)		(245	)		(270	)		110	%
Depreciation		—			—			—			—%
Loss from operations	$	(533	)	$	(266	)	$	(267	)		100	%

To date, the Pharmaceuticals segment has not generated any revenues. The entirety of the expenses in the Pharmaceuticals segment relate to the activities of LipoMedix and Barer. Research and development increased for the three months ended October 31, 2020 compared to the three months ended October 31, 2019 due to Barer commencing operations in fiscal 2020. As of October 31, 2020 and 2019, we held a 68% and 52% interest, respectively, in LipoMedix and consolidated our majority interest in LipoMedix.

Real Estate Segment

Our consolidated income and expenses for our Real Estate segment were as follows:

	Three Months Ended October 31,						Change
	2020			2019			$			%
	*(unaudited, in thousands)*
Rental – Third Party	$	236		$	346		$	(110	)		(32	)%
Rental – Related Party		520			520			—			—%
Parking		177			224			(47	)		(21	)%
Other		120			120			—			—%
Selling, general and administrative		(2,574	)		(2,020	)		(554	)		27	%
Depreciation		(437	)		(466	)		29			(6	)%
Loss from operations	$	(1,958	)	$	(1,276	)	$	(682	)		53	%

Revenues. Rental and Parking revenues decreased by approximately $157,000 for the three months ended October 31, 2020, compared to the three months ended October 31, 2019, primarily due to the sale of the building in Piscataway and the related reduced rental income, in addition to the decrease in parking as the majority of the customers who were utilizing the parking garage are now working from home due to COVID-19.

Selling, general and administrative expenses. Selling, general and administrative expenses consists mainly of payroll, benefits, facilities, consulting and professional fees. The increase in selling, general and administrative expenses for the three months ended October 31, 2020, compared to the three months ended October 31, 2019 is primarily due to increased insurance and real estate tax costs.

Depreciation expenses. Depreciation expenses decreased for the three months ended October 31, 2020, compared to the three months ended October 31, 2019 due to the sale of the building in Piscataway, New Jersey.

Consolidated Operations

Our consolidated income and expense line items below income from operations were as follows:

	Three Months Ended October 31,						Change
	2020			2019			$			%
	*(unaudited, in thousands)*
Loss from operations	$	(2,491	)	$	(1,542	)	$	(949	)		62	%
Interest expense, net		—			(64	)		64			(100	)%
Net loss resulting from foreign exchange transactions		—			(5	)		5			(100	)%
Gain on sale of building		749			—			749			100	%
Impairment of investments - Other Pharmaceuticals		(724	)		—			(724	)		(100	)%
Unrealized gain (loss) on investments - Hedge Funds		944			(37	)		981			(2651	)%
Loss before income taxes		(1,522	)		(1,648	)		126			8	%
Provision for income taxes		(5	)		(4	)		(1	)		25	%
Equity in earnings of RP Finance		96			—			96			100	%
Consolidated net loss		(1,431	)		(1,652	)		221			(13	)%
Net loss (income) attributable to noncontrolling interests		15			(54	)		69			(128	)%
Net loss attributable to Rafael Holdings, Inc.	$	(1,446	)	$	(1,598	)	$	152			(10	)%

Interest expense, net. Interest expense, net was $0 for the three months ended October 31, 2020 and $64 thousand for the year months ended October 31, 2019. The reduction is due to the decrease in interest expense related to the conversion of the convertible note in January 2019.

Net loss resulting from foreign exchange transactions. Net loss resulting from foreign exchange transactions is composed entirely from changes in movements in New Israeli Shekels relative to the U.S. Dollar.

Impairment of investments - Other Pharmaceuticals. The Company recorded an impairment loss of $724 thousand related to the Company’s investment using the measurement alternative for the three months ended October 31, 2020.

Unrealized gain (loss) on investments - Hedge Funds. The Company recorded unrealized gains of approximately $944 thousand and unrealized losses of $37 thousand for the three months ended October 31, 2020 and 2019, respectively.

Gain on sale of building. In August 2020, the Company sold a building located in Piscataway, New Jersey, and recognized a gain on the sale of approximately $749 thousand.

Equity in earnings of RP Finance. The Company recognized approximately $96 thousand in income from its ownership interests of 37.5% in RP Finance for the three months ended October 31, 2020.

Net loss (income) attributable to noncontrolling interests. The change in the net loss (income) attributable to noncontrolling interests was due to LipoMedix for the three months ended October 31, 2020 and 2019, respectively.

Liquidity and Capital Resources

General

As of October 31, 2020, we had cash and cash equivalents of $7.2 million. We expect our cash from operations in the next 12 months and the balance of cash and cash equivalents that we held as of October 31, 2020 in addition to the subsequent $13 million obtained in December 2020 from Share Purchase Agreements related to the sale of the Company’s Class B common stock (see Note 17) to be sufficient to meet our currently anticipated working capital, research and development, and capital expenditure requirements during the next 12 months from the issuance of these consolidated financial statements.

	Three Months Ended October, 31
	2020			2019
	*(unaudited, in thousands)*
Cash flows (used in) provided by
Operating activities	$	(2,653	)	$	(936	)
Investing activities		3,638			(321	)
Financing activities		43			—
Effect of exchange rates on cash and cash equivalents		(3	)		4
Decrease in cash and cash equivalents	$	1,025		$	(1,253	)

Operating Activities

The increase in cash used in operating activities for the three months ended October 31, 2020 as compared to for the three months ended October 31, 2019 was primarily related to the net loss, and different impact from non-cash items, primarily the unrealized gain on investments - Hedge Funds and the gain on the sale of the Piscataway building.

Investing Activities

Cash provided by investing activities for the three months ended October 31, 2020 was primarily related to the proceeds from the sale of the building in Piscataway, New Jersey in August 2020 and proceeds from hedge funds, offset by the payment to fund the RP Finance line of credit.

Cash used in investing activities for the three months ended October 31, 2019 related to building improvements made to our real estate holdings.

Financing Activities

Cash provided by financing activities for the three months ended October 31, 2020 was related to proceeds from the exercise of options to purchase Class B common stock of the Company.

There was no cash provided by or used in financing activities for the three months ended October 31, 2019.

We do not anticipate paying dividends on our common stock until we achieve sustainable profitability and retain certain minimum cash reserves. The payment of dividends in any specific period will be at the sole discretion of our Board of Directors.

Trends and Uncertainties – COVID-19

We actively monitor the COVID-19 pandemic and its potential impact on our operations and those of our holdings. Although our operations are mainly in the United States, we have assets outside of the United States, and some of our pharmaceutical holdings conduct operations, manufacturing and clinical trial activities in Europe and Asia.

We had one tenant that has not paid rent for August 2020 due to the New Jersey state gym closures; however, the tenant subsequently resumed rent payments. There is a general degree of uncertainty in the national commercial real estate market based on the COVID-19 pandemic and as a result there is a potential impact to the value of our real estate portfolio as well as efforts to monetize those assets.

Critical Accounting Policies and Estimates

We have chosen accounting policies that we believe are appropriate to accurately and fairly report our operating results and financial condition in conformity with U.S. GAAP. We apply these accounting policies in a consistent manner. Our significant accounting policies are discussed in Note 1, “Description of Business and Summary of Significant Accounting Policies,” to our consolidated financial statements included in our 2020 Form 10-K.

The application of critical accounting policies requires that we make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. These estimates and assumptions are based on historical and other factors believed to be reasonable under the circumstances. We evaluate these estimates and assumptions on an ongoing basis and may retain outside consultants to assist in our evaluation. If actual results ultimately differ from previous estimates, the revisions are included in results of operations in the period in which the actual amounts become known. The critical accounting policies that involve the most significant management judgments and estimates used in preparation of our consolidated financial statements, or are the most sensitive to change from outside factors, are discussed in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the Company’s Annual Report on Form 10-K for fiscal 2020 (“2020 Form 10-K”). There have been no material changes in our critical accounting policies and procedures during the three months ended October 31, 2020.

Off-Balance Sheet Arrangements

We do not have any “off-balance sheet arrangements,” as defined in relevant SEC regulations that are reasonably likely to have a current or future effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.

IDT is generally responsible for our federal, state, local and foreign income taxes for periods before and including the Spin-Off. We are generally responsible for all other taxes relating to our business. We and IDT will each generally be responsible for managing those disputes that relate to the taxes for which each of us is responsible and, under certain circumstances, may jointly control any dispute relating to taxes for which both of us are responsible.

Item 3. Quantitative and Qualitative Disclosures about Market Risks.

There have been no significant changes in our market risk exposures from those described in Item 7A of our 2020 Form 10-K.

We are monitoring the potential impacts of the COVID-19 pandemic on our business. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact on the global financial markets may reduce our ability to access capital, which could negatively impact our long-term liquidity.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures. Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of October 31, 2020.

Changes in Internal Control over Financial Reporting. There were no changes in our internal control over financial reporting during the quarter ended October 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II. OTHER INFORMATION

Item 1. Legal Proceedings.

Legal proceedings in which we are involved are more fully described in Note 14 to the Consolidated Financial Statements included in Item 1 to Part I of this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors

Item 1A Risk Factors contained in our 2020 Form 10-K includes a discussion of risk factors related to investment in our common stock which is incorporated herein. There were no material changes from the risk factors associated with our business previously disclosed in Part I, Item 1A “Risk Factors” of our 2020 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit Number		Description

31.1*		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB*		XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document

Filed or furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: December 15, 2020	Rafael Holdings, Inc.

	By:	/s/ Howard S. Jonas
		Howard S. Jonas Chief Executive Officer

	By:	/s/ David Polinsky
		David Polinsky Chief Financial Officer

EX-31.1 2 f10q1020ex31-1_rafaelholding.htm CERTIFICATION

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Howard S. Jonas, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Rafael Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: December 15, 2020

/s/ Howard S. Jonas
Howard S. Jonas
Chief Executive Officer

EX-31.2 3 f10q1020ex31-2_rafaelholding.htm CERTIFICATION

EXHIBIT 31.2

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David Polinsky, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Rafael Holdings, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: December 15, 2020

/s/ David Polinsky
David Polinsky
Chief Financial Officer

EX-32.1 4 f10q1020ex32-1_rafaelholding.htm CERTIFICATION

EXHIBIT 32.1

Certification Pursuant to
18 U.S.C. Section 1350
(as Adopted Pursuant to Section 906 of
the Sarbanes-Oxley Act Of 2002)

In connection with the Quarterly Report of Rafael Holdings, Inc. (the “Company”) on Form 10-Q for the quarter ended October 31, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, Howard S. Jonas, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: December 15, 2020

/s/ Howard S. Jonas
Howard S. Jonas
Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Rafael Holdings, Inc. and will be retained by Rafael Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 f10q1020ex32-2_rafaelholding.htm CERTIFICATION

EXHIBIT 32.2

Certification Pursuant to
18 U.S.C. Section 1350
(as Adopted Pursuant to Section 906 of
the Sarbanes-Oxley Act Of 2002)

In connection with the Quarterly Report of Rafael Holdings, Inc. (the “Company”) on Form 10-Q for the quarter ended October 31, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, David Polinsky, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: December 15, 2020

/s/ David Polinsky
David Polinsky
Chief Financial Officer

EX-101.INS 6 rfl-20201031.xml XBRL INSTANCE FILE 0001713863 2020-08-01 2020-10-31 0001713863 us-gaap:CommonClassAMember 2020-12-14 0001713863 us-gaap:CommonClassBMember 2020-12-14 0001713863 2020-10-31 0001713863 2020-07-31 0001713863 us-gaap:CommonClassAMember 2020-10-31 0001713863 us-gaap:CommonClassAMember 2020-07-31 0001713863 us-gaap:CommonClassBMember 2020-10-31 0001713863 us-gaap:CommonClassBMember 2020-07-31 0001713863 2019-08-01 2019-10-31 0001713863 us-gaap:AdditionalPaidInCapitalMember 2020-07-31 0001713863 us-gaap:RetainedEarningsMember 2020-07-31 0001713863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-31 0001713863 us-gaap:NoncontrollingInterestMember 2020-07-31 0001713863 us-gaap:CommonClassAMember 2020-08-01 2020-10-31 0001713863 us-gaap:CommonClassBMember 2020-08-01 2020-10-31 0001713863 us-gaap:AdditionalPaidInCapitalMember 2020-08-01 2020-10-31 0001713863 us-gaap:RetainedEarningsMember 2020-08-01 2020-10-31 0001713863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-08-01 2020-10-31 0001713863 us-gaap:NoncontrollingInterestMember 2020-08-01 2020-10-31 0001713863 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001713863 us-gaap:RetainedEarningsMember 2020-10-31 0001713863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-31 0001713863 us-gaap:NoncontrollingInterestMember 2020-10-31 0001713863 us-gaap:CommonClassAMember 2019-07-31 0001713863 us-gaap:CommonClassBMember 2019-07-31 0001713863 us-gaap:AdditionalPaidInCapitalMember 2019-07-31 0001713863 us-gaap:RetainedEarningsMember 2019-07-31 0001713863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-31 0001713863 us-gaap:NoncontrollingInterestMember 2019-07-31 0001713863 2019-07-31 0001713863 us-gaap:CommonClassAMember 2019-08-01 2019-10-31 0001713863 us-gaap:CommonClassBMember 2019-08-01 2019-10-31 0001713863 us-gaap:AdditionalPaidInCapitalMember 2019-08-01 2019-10-31 0001713863 us-gaap:RetainedEarningsMember 2019-08-01 2019-10-31 0001713863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-08-01 2019-10-31 0001713863 us-gaap:NoncontrollingInterestMember 2019-08-01 2019-10-31 0001713863 us-gaap:CommonClassAMember 2019-10-31 0001713863 us-gaap:CommonClassBMember 2019-10-31 0001713863 us-gaap:AdditionalPaidInCapitalMember 2019-10-31 0001713863 us-gaap:RetainedEarningsMember 2019-10-31 0001713863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-31 0001713863 us-gaap:NoncontrollingInterestMember 2019-10-31 0001713863 2019-10-31 0001713863 rfl:PharmaHoldingsLLCMember 2020-08-01 2020-10-31 0001713863 rfl:RafaelHoldingsIncMember 2020-08-01 2020-10-31 0001713863 rfl:BroadAtlanticAssociatesLLCMember 2020-08-01 2020-10-31 0001713863 rfl:IDT225OldNBRoadLLCMember 2020-08-01 2020-10-31 0001713863 rfl:IDTREHoldingsLtdMember 2020-08-01 2020-10-31 0001713863 rfl:RafaelRealtyHoldingsIncMember 2020-08-01 2020-10-31 0001713863 rfl:BarerInstituteIncMember 2020-08-01 2020-10-31 0001713863 rfl:TheBarerInstituteLLCMember 2020-08-01 2020-10-31 0001713863 rfl:HillviewAvenueRealtyJVMember 2020-08-01 2020-10-31 0001713863 rfl:HillviewAvenueRealtyLLCMember 2020-08-01 2020-10-31 0001713863 rfl:LevcoPharmaceuticalsLtdMember 2020-08-01 2020-10-31 0001713863 rfl:FarberPartnersLLCMember 2020-08-01 2020-10-31 0001713863 rfl:LipoMedixPharmaceuticalsLtdMember 2020-08-01 2020-10-31 0001713863 rfl:CSPharmaHoldingsLLCMember 2020-08-01 2020-10-31 0001713863 rfl:RafaelPharmaceuticalsMember 2020-08-01 2020-10-31 0001713863 rfl:RafaelPharmaceuticalsMember 2020-08-01 2020-10-31 0001713863 rfl:CSPharmaHoldingsLLCMember rfl:SeriesDConvertiblePreferredStockMember 2020-08-01 2020-10-31 0001713863 2019-01-01 2019-01-31 0001713863 2019-01-31 0001713863 rfl:SeriesDConvertiblePreferredStockMember 2020-08-01 2020-10-31 0001713863 rfl:PharmaHoldingsMember 2020-08-01 2020-10-31 0001713863 rfl:HowardJonasMember 2020-10-31 0001713863 rfl:RafaelPharmaceuticalsMember rfl:HowardJonasMember 2020-10-31 0001713863 rfl:PharmaHoldingsMember 2020-08-01 2020-10-31 0001713863 rfl:PurchaseAgreementMember 2020-05-01 2020-05-13 0001713863 rfl:AltiraMember 2020-08-01 2020-10-31 0001713863 rfl:AltiraMember 2020-10-31 0001713863 rfl:AltiraMember 2019-08-01 2020-07-31 0001713863 us-gaap:LineOfCreditMember 2020-02-03 0001713863 us-gaap:LineOfCreditMember 2020-01-27 2020-02-03 0001713863 rfl:RafaelPharmaceuticalsMember 2020-10-31 0001713863 2020-08-01 2020-08-31 0001713863 rfl:RafaelPharmaceuticalsMember 2020-08-31 0001713863 rfl:RafaelPharmaceuticalsMember 2020-09-30 0001713863 2020-10-01 2020-10-31 0001713863 2019-11-30 0001713863 2020-01-31 0001713863 2020-03-31 0001713863 2020-05-20 0001713863 2020-05-01 2020-05-20 0001713863 2019-11-13 0001713863 2020-01-01 2020-01-21 0001713863 2020-03-15 2020-03-27 0001713863 rfl:LipomedixPharmaceuticalsLtdMember srt:MinimumMember 2020-05-20 0001713863 rfl:LipomedixPharmaceuticalsLtdMember srt:MaximumMember 2020-05-20 0001713863 us-gaap:FairValueInputsLevel1Member 2020-10-31 0001713863 us-gaap:FairValueInputsLevel2Member 2020-10-31 0001713863 us-gaap:FairValueInputsLevel3Member 2020-10-31 0001713863 us-gaap:FairValueInputsLevel1Member 2020-07-31 0001713863 us-gaap:FairValueInputsLevel2Member 2020-07-31 0001713863 us-gaap:FairValueInputsLevel3Member 2020-07-31 0001713863 rfl:AccruedRentalIncomeMember 2020-10-31 0001713863 rfl:AccruedRentalIncomeMember 2020-07-31 0001713863 rfl:NoncurrentAccruedRentalIncomeMember 2020-10-31 0001713863 rfl:NoncurrentAccruedRentalIncomeMember 2020-07-31 0001713863 us-gaap:PropertyPlantAndEquipmentMember 2020-08-01 2020-10-31 0001713863 us-gaap:PropertyPlantAndEquipmentMember 2019-08-01 2019-10-31 0001713863 us-gaap:PropertyPlantAndEquipmentMember 2020-10-31 0001713863 us-gaap:PropertyPlantAndEquipmentMember 2020-07-31 0001713863 rfl:DueToIDTMember 2020-08-01 2020-10-31 0001713863 rfl:DueToIDTMember 2020-10-31 0001713863 rfl:IdtRafaelHoldingsLlcMember 2020-10-31 0001713863 rfl:DueToIDTMember 2019-08-01 2019-10-31 0001713863 rfl:RafaelPharmaceuticalsMember 2020-10-31 0001713863 rfl:RafaelPharmaceuticalsMember 2019-10-31 0001713863 rfl:RafaelPharmaceuticalsMember 2020-07-31 0001713863 rfl:CSPharmaHoldingsLLCMember 2018-09-01 2018-09-30 0001713863 rfl:IdtRafaelHoldingsLlcMember 2018-11-05 0001713863 rfl:IdtRafaelHoldingsLlcMember 2018-11-01 2018-11-05 0001713863 rfl:HowardJonasMember 2018-11-05 0001713863 2018-11-06 2018-11-15 0001713863 rfl:IdtRafaelHoldingsLlcMember 2019-01-10 0001713863 rfl:IdtRafaelHoldingsLlcMember 2019-01-02 2019-01-10 0001713863 rfl:HowardJonasMember 2019-01-10 0001713863 rfl:IdtRafaelHoldingsLlcMember 2019-01-23 0001713863 rfl:IdtRafaelHoldingsLlcMember 2019-01-04 2019-01-23 0001713863 rfl:HowardJonasMember 2019-01-23 0001713863 rfl:OfficersMember us-gaap:CommonClassBMember 2020-01-05 2020-01-29 0001713863 2019-08-01 2020-07-31 0001713863 2020-08-02 2020-08-31 0001713863 rfl:PharmaceuticalsMember 2020-08-01 2020-10-31 0001713863 us-gaap:RealEstateMember 2020-08-01 2020-10-31 0001713863 rfl:PharmaceuticalsMember 2019-08-01 2019-10-31 0001713863 us-gaap:RealEstateMember 2019-08-01 2019-10-31 0001713863 pf0:US 2020-10-31 0001713863 pf0:IL 2020-10-31 0001713863 us-gaap:CorporateMember 2020-10-31 0001713863 pf0:US 2020-07-31 0001713863 pf0:IL 2020-07-31 0001713863 us-gaap:CorporateMember 2020-07-31 0001713863 2018-09-02 2018-09-17 0001713863 us-gaap:CommonClassBMember 2018-11-15 0001713863 2018-11-01 2018-11-15 0001713863 us-gaap:CommonClassBMember 2019-08-31 0001713863 us-gaap:CommonClassBMember 2019-08-01 2019-08-31 0001713863 rfl:TwoThousandEighteenEquityIncentivePlanMember 2020-08-01 2020-10-31 0001713863 us-gaap:RestrictedStockMember 2020-08-01 2020-10-31 0001713863 rfl:RelatedPartiesMember 2020-07-31 0001713863 rfl:OtherMember 2020-07-31 0001713863 us-gaap:SubsequentEventMember 2020-12-03 2020-12-07 0001713863 us-gaap:SubsequentEventMember 2020-12-07 0001713863 us-gaap:SubsequentEventMember 2020-12-01 2020-12-10 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:sqm 50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC. 000-55863 Yes false false --07-31 Q1 2021 2020-10-31 10-Q 0001713863 true Non-accelerated Filer DE Yes Rafael Holdings, Inc. false true 787163 15044547

7231000

6206000

309000

267000

240000 118000

460000

273000

2968000

8240000

9832000

44141000

44433000

288000 192000

1875000

70018000

477000 1201000 6454000 7510000

6000

1575000 1575000

1550000

1580000

134618000

136347000

1155000

921000

443000

1191000

3500000 3500000

141000

115000

30000

5269000

5727000

33000

92000

5302000

5819000

8000

149000

129393000

129136000

-17701000

-16255000

3724000

3762000

115573000

116800000

13743000

13728000

129316000

130528000

134618000

136347000

256000

218000

0.01

35000000

787163

0.01

200000000

15050609

15034598

15044547

15028536

236000

346000

520000

177000 224000 120000 120000

1053000

1210000

2592000

2041000

515000

245000

437000

466000

-2491000

-1542000

-64000

-5000

749000

724000

-944000 37000

-1522000

-1648000

5000

4000

96000

-1431000

-1652000

15000

-54000

-1446000

-1598000

-38000

6000

-1469000

-1646000

21000

2000

-1490000

-1648000

-0.09

-0.10

15822722

15640683

787163

8000

15028536

149000

129136000

-16255000

3762000

13728000

-1446000

15000

7261

214000

8750

43000

-38000

787163

8000

15044547

149000

129393000

-17701000

3724000

13743000

787163

8000

13142502

131000

112898000

-5840000

3784000

13783000

124764000

-1598000

-54000

5000

94000

1849749

18000

15650000

15668000

82000 82000

6000

787163

8000

14997251

149000

128642000

-7438000

3790000

13811000

138962000

437000

466000

6000

1000

944000 -37000

38000

48000

214000

94000

54000

749000

80000

-173000

187000

-217000

-30000

289000

-490000

-196000

122000

26000

-12000

30000

-37000

-160000 -59000

-2653000

-936000

145000

321000

1875000

3658000

2000000

3638000

-321000

43000

-3000

4000

1025000

-1253000

12024000

10771000

82000 15668000

NOTE 1 – DESCRIPTION OF BUSINESS Rafael Holdings, Inc. (“Rafael Holdings” or the “Company”), a Delaware corporation, owns interests in pre-clinical and clinical stage pharmaceutical companies and commercial real estate assets. The assets are operated as two separate lines of business. The pharmaceutical holdings include preferred and common equity interests and a warrant to purchase additional equity interests in Rafael Pharmaceuticals, Inc., or Rafael Pharmaceuticals, which is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells; and, a majority equity interest in LipoMedix Pharmaceuticals Ltd., or LipoMedix, a clinical stage oncological pharmaceutical company based in Israel. In addition, in 2019, we established the Barer Institute (“Barer”), a wholly-owned early stage venture focused on developing a pipeline of therapeutic compounds, including compounds to regulate cancer metabolism. The venture is pursuing collaborative research agreements with leading scientists from top academic institutions to develop other early stage ventures. In addition, we have recently initiated efforts to develop other early stage pharmaceutical ventures. The commercial real estate holdings consist of a building at 520 Broad Street in Newark, New Jersey that serves as headquarters for the Company and certain other entities and hosts other tenants and an associated 800-car public garage, and a portion of a building in Israel. In August 2020, the Company sold an office/data center building in Piscataway, New Jersey, which was classified as held for sale at July 31, 2020. The “Company” in these consolidated financial statements refers to Rafael Holdings on a consolidated basis. All significant intercompany accounts and transactions have been eliminated in consolidation. All majority-owned subsidiaries are consolidated with all intercompany transactions and balances being eliminated in consolidation or combination. The entities included in these consolidated financial statements are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: black 1.5pt solid">Company</td> <td style="padding-bottom: 1.5pt"> </td> <td style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center">Country of Incorporation</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center">Percentage Owned</td> <td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; padding-left: 2.65pt">Rafael Holdings, Inc.</td> <td style="width: 1%"> </td> <td style="width: 42%; padding-left: 2.65pt">United States – Delaware</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">100</td> <td style="white-space: nowrap; width: 2%">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">Broad Atlantic Associates, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 2.65pt">IDT 225 Old NB Road, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">IDT R.E. Holdings Ltd.</td> <td> </td> <td style="padding-left: 2.65pt">Israel</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 2.65pt">Rafael Holdings Realty, Inc.</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">Barer Institute, Inc.</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 2.65pt">The Barer Institute, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">Hillview Avenue Realty, JV</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 2.65pt">Hillview Avenue Realty, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">Levco Pharmaceuticals Ltd.</td> <td> </td> <td style="padding-left: 2.65pt">Israel</td> <td> </td> <td> </td> <td style="text-align: right">95</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 2.65pt">Farber Partners, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">93</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">Pharma Holdings, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">90</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 2.65pt">LipoMedix Pharmaceuticals Ltd.</td> <td> </td> <td style="padding-left: 2.65pt">Israel</td> <td> </td> <td> </td> <td style="text-align: right">68</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">CS Pharma Holdings, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">45</td> <td style="white-space: nowrap">%*</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.</td> </tr></table>

0.50 0.90

0.45

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: black 1.5pt solid">Company</td> <td style="padding-bottom: 1.5pt"> </td> <td style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center">Country of Incorporation</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center">Percentage Owned</td> <td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; padding-left: 2.65pt">Rafael Holdings, Inc.</td> <td style="width: 1%"> </td> <td style="width: 42%; padding-left: 2.65pt">United States – Delaware</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">100</td> <td style="white-space: nowrap; width: 2%">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">Broad Atlantic Associates, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 2.65pt">IDT 225 Old NB Road, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">IDT R.E. Holdings Ltd.</td> <td> </td> <td style="padding-left: 2.65pt">Israel</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 2.65pt">Rafael Holdings Realty, Inc.</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">Barer Institute, Inc.</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 2.65pt">The Barer Institute, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">Hillview Avenue Realty, JV</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 2.65pt">Hillview Avenue Realty, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">Levco Pharmaceuticals Ltd.</td> <td> </td> <td style="padding-left: 2.65pt">Israel</td> <td> </td> <td> </td> <td style="text-align: right">95</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 2.65pt">Farber Partners, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">93</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">Pharma Holdings, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">90</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 2.65pt">LipoMedix Pharmaceuticals Ltd.</td> <td> </td> <td style="padding-left: 2.65pt">Israel</td> <td> </td> <td> </td> <td style="text-align: right">68</td> <td style="white-space: nowrap">%</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 2.65pt">CS Pharma Holdings, LLC</td> <td> </td> <td style="padding-left: 2.65pt">United States – Delaware</td> <td> </td> <td> </td> <td style="text-align: right">45</td> <td style="white-space: nowrap">%*</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.</td> </tr></table> United States - Delaware 1.00 United States - Delaware 1.00 United States - Delaware 1.00 Israel 1.00 United States - Delaware 1.00 United States - Delaware 1.00 United States - Delaware 1.00 United States - Delaware 1.00 United States - Delaware 1.00 Israel 0.95 United States - Delaware 0.93 United States - Delaware 0.90 Israel 0.68 United States - Delaware 0.45

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal 2020 refers to the fiscal year ended July 31, 2020). Operating results for the three months ended October 31, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2021. The balance sheet at July 31, 2020 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2020, or the 2020 Form 10-K, as filed with the U.S. Securities and Exchange Commission (“SEC”). Use of Estimates     The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates. Risks and Uncertainties - COVID-19 In December 2019, a new coronavirus, now known as COVID-19, which has proved to be highly contagious, emerged in Wuhan, China and has since spread around the globe. The Company actively monitors the outbreak and its potential impact on its operations and those of the Company’s holdings. The impacts on the operations and specifically the ongoing clinical trials of our pharmaceutical holdings have been actively managed by respective pharmaceutical management teams who have worked closely with the appropriate regulatory agencies to continue clinical trial activities with as minimal impact as possible from the pandemic, including receiving waivers for certain clinical trial activities from the respective regulatory agencies to continue the studies. The Company has one tenant that has not paid rent for August 2020 due to the New Jersey state gym closures; however, the tenant subsequently resumed rent payments. There is a general degree of uncertainty in the national commercial real estate market based on the COVID-19 pandemic and as a result there is a potential impact to the value of the Company’s real estate portfolio as well as efforts to monetize those assets. The Company has implemented a number of measures to protect the health and safety of our workforce including a mandatory work-from-home policy for our workforce who can perform their jobs from home as well as restrictions on business travel and workplace and in-person meetings. Due to both known and unknown risks, including quarantines, closures and other restrictions resulting from the outbreak, operations and those of the Company’s holdings may be adversely impacted. Additionally, as there is an evolving nature to the COVID-19 situation, we cannot reasonably assess or predict at this time the full extent of the negative impact that the COVID-19 pandemic may have on our business, financial condition, results of operations and cash flows. The impact will depend on future developments such as the ultimate duration and the severity of the spread of the COVID-19 pandemic in the U.S. and globally, the effectiveness of federal, state, local and foreign government actions on mitigation and spread of COVID-19, the pandemic’s impact on the U.S. and global economies, changes in our customers’ behavior emanating from the pandemic and how quickly we can resume our normal operations, among others. For all these reasons, the Company may incur expenses or delays relating to such events outside of the Company’s control, which could have a material adverse impact on the Company’s business. Investments The method of accounting applied to long-term investments, whether consolidated, equity or cost, involves an evaluation of the significant terms of each investment that explicitly grant or suggest evidence of control or influence over the operations of the investee and also includes the identification of any variable interests in which the Company is the primary beneficiary. The consolidated financial statements include the Company’s controlled affiliates. All significant intercompany accounts and transactions between the consolidated affiliates are eliminated. Investments in businesses that the Company does not control, but in which the Company has the ability to exercise significant influence over operating and financial matters, are accounted for using the equity method. Investments in which the Company does not have the ability to exercise significant influence over operating and financial matters are accounted for using the cost method. The Company periodically evaluates its investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded in the accompanying consolidated statements of operations and comprehensive loss, and a new basis in the investment is established. Variable Interest Entities In accordance with Accounting Standards Codification (“ASC”) 810, Consolidation, the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities (“VIEs”). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE. If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Cost Method Investments - Rafael Pharmaceuticals (see Note 3) is a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals’ economic performance. Cost method investments are presented as “Investments - Rafael Pharmaceuticals.” Equity Method Investments - RP Finance, LLC (“RP Finance”), (see Note 5), has been identified as a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of RP Finance that most significantly impact RP Finance’s economic performance and, therefore, is not required to consolidate RP Finance. The Company accounts for its investment in RP Finance using the equity method of accounting. Revenue Recognition The Company applies the five-step approach as described in ASC 606, Revenue from Contracts with Customers, which consists of the following: (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations in the contract and (v) recognizing revenue when (or as) the entity satisfies a performance obligation. The Company disaggregates its revenue by source within its consolidated statements of operations and comprehensive loss. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing office and parking space to tenants at its properties. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recorded together with rental income on the consolidated statements of operations and comprehensive loss which is also consistent with the guidance under ASC 842, Leases. Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within other assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements. The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company’s performance obligation is satisfied, consistent with the Company’s previous accounting. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due. Research and Development Costs Research and development costs and expenses incurred by consolidated entities consist primarily of salaries and related personnel expenses, stock-based compensation, fees paid to external service providers, laboratory supplies, costs for facilities and equipment, license costs, and other costs for research and development activities. Research and development expenses are recorded in operating expenses in the period in which they are incurred. Estimates have been used in determining the liability for certain costs where services have been performed but not yet invoiced. The Company monitors levels of performance under each significant contract for external service providers, including the extent of patient enrollment and other activities through communications with the service providers to reflect the actual amount expended. Contingent milestone payments associated with acquiring rights to intellectual property are recognized when probable and estimable. These amounts are expensed to research and development when there is no alternative future use associated with the intellectual property. Recently Issued Accounting Standards Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, that changes the impairment model for most financial assets and certain other instruments. For receivables, loans and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowance for losses. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to current practice, except the losses will be recognized as allowances instead of reductions in the amortized cost of the securities. In addition, an entity will have to disclose significantly more information about allowances, credit quality indicators and past due securities. The new standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and will be applied as a cumulative-effect adjustment to retained earnings. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and intends to adopt the standard on August 1, 2023.

Basis of Presentation The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal 2020 refers to the fiscal year ended July 31, 2020). Operating results for the three months ended October 31, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2021. The balance sheet at July 31, 2020 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2020, or the 2020 Form 10-K, as filed with the U.S. Securities and Exchange Commission (“SEC”).

Use of Estimates     The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates.

Risks and Uncertainties - COVID-19 In December 2019, a new coronavirus, now known as COVID-19, which has proved to be highly contagious, emerged in Wuhan, China and has since spread around the globe. The Company actively monitors the outbreak and its potential impact on its operations and those of the Company’s holdings. The impacts on the operations and specifically the ongoing clinical trials of our pharmaceutical holdings have been actively managed by respective pharmaceutical management teams who have worked closely with the appropriate regulatory agencies to continue clinical trial activities with as minimal impact as possible from the pandemic, including receiving waivers for certain clinical trial activities from the respective regulatory agencies to continue the studies. The Company has one tenant that has not paid rent for August 2020 due to the New Jersey state gym closures; however, the tenant subsequently resumed rent payments. There is a general degree of uncertainty in the national commercial real estate market based on the COVID-19 pandemic and as a result there is a potential impact to the value of the Company’s real estate portfolio as well as efforts to monetize those assets. The Company has implemented a number of measures to protect the health and safety of our workforce including a mandatory work-from-home policy for our workforce who can perform their jobs from home as well as restrictions on business travel and workplace and in-person meetings. Due to both known and unknown risks, including quarantines, closures and other restrictions resulting from the outbreak, operations and those of the Company’s holdings may be adversely impacted. Additionally, as there is an evolving nature to the COVID-19 situation, we cannot reasonably assess or predict at this time the full extent of the negative impact that the COVID-19 pandemic may have on our business, financial condition, results of operations and cash flows. The impact will depend on future developments such as the ultimate duration and the severity of the spread of the COVID-19 pandemic in the U.S. and globally, the effectiveness of federal, state, local and foreign government actions on mitigation and spread of COVID-19, the pandemic’s impact on the U.S. and global economies, changes in our customers’ behavior emanating from the pandemic and how quickly we can resume our normal operations, among others. For all these reasons, the Company may incur expenses or delays relating to such events outside of the Company’s control, which could have a material adverse impact on the Company’s business.

Investments The method of accounting applied to long-term investments, whether consolidated, equity or cost, involves an evaluation of the significant terms of each investment that explicitly grant or suggest evidence of control or influence over the operations of the investee and also includes the identification of any variable interests in which the Company is the primary beneficiary. The consolidated financial statements include the Company’s controlled affiliates. All significant intercompany accounts and transactions between the consolidated affiliates are eliminated. Investments in businesses that the Company does not control, but in which the Company has the ability to exercise significant influence over operating and financial matters, are accounted for using the equity method. Investments in which the Company does not have the ability to exercise significant influence over operating and financial matters are accounted for using the cost method. The Company periodically evaluates its investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded in the accompanying consolidated statements of operations and comprehensive loss, and a new basis in the investment is established.

Variable Interest Entities In accordance with Accounting Standards Codification (“ASC”) 810, Consolidation, the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities (“VIEs”). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE. If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Cost Method Investments - Rafael Pharmaceuticals (see Note 3) is a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals’ economic performance. Cost method investments are presented as “Investments - Rafael Pharmaceuticals.” Equity Method Investments - RP Finance, LLC (“RP Finance”), (see Note 5), has been identified as a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of RP Finance that most significantly impact RP Finance’s economic performance and, therefore, is not required to consolidate RP Finance. The Company accounts for its investment in RP Finance using the equity method of accounting.

Revenue Recognition The Company applies the five-step approach as described in ASC 606, Revenue from Contracts with Customers, which consists of the following: (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations in the contract and (v) recognizing revenue when (or as) the entity satisfies a performance obligation. The Company disaggregates its revenue by source within its consolidated statements of operations and comprehensive loss. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing office and parking space to tenants at its properties. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recorded together with rental income on the consolidated statements of operations and comprehensive loss which is also consistent with the guidance under ASC 842, Leases. Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within other assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements. The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company’s performance obligation is satisfied, consistent with the Company’s previous accounting. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due.

Research and Development Costs Research and development costs and expenses incurred by consolidated entities consist primarily of salaries and related personnel expenses, stock-based compensation, fees paid to external service providers, laboratory supplies, costs for facilities and equipment, license costs, and other costs for research and development activities. Research and development expenses are recorded in operating expenses in the period in which they are incurred. Estimates have been used in determining the liability for certain costs where services have been performed but not yet invoiced. The Company monitors levels of performance under each significant contract for external service providers, including the extent of patient enrollment and other activities through communications with the service providers to reflect the actual amount expended. Contingent milestone payments associated with acquiring rights to intellectual property are recognized when probable and estimable. These amounts are expensed to research and development when there is no alternative future use associated with the intellectual property.

Recently Issued Accounting Standards Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, that changes the impairment model for most financial assets and certain other instruments. For receivables, loans and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowance for losses. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to current practice, except the losses will be recognized as allowances instead of reductions in the amortized cost of the securities. In addition, an entity will have to disclose significantly more information about allowances, credit quality indicators and past due securities. The new standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and will be applied as a cumulative-effect adjustment to retained earnings. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and intends to adopt the standard on August 1, 2023.

NOTE 3 – INVESTMENT IN RAFAEL PHARMACEUTICALS Rafael Pharmaceuticals is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The Company owns equity interests and rights in Rafael Pharmaceuticals through a 90%-owned non-operating subsidiary, Pharma Holdings, LLC, or Pharma Holdings. Pharma Holdings owns 50% of CS Pharma Holdings, LLC, or CS Pharma, a non-operating entity that owns equity interests in Rafael Pharmaceuticals. Accordingly, the Company holds an effective 45% indirect interest in the assets held by CS Pharma. Howard Jonas, Chairman of the Board and Chief Executive Officer of the Company, and Chairman of the Board of Rafael Pharmaceuticals, owns 10% of Pharma Holdings. Pharma Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase ownership to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments, and will expire upon the earlier of June 30, 2021, a qualified initial public offering, or liquidation event of Rafael Pharmaceuticals. On March 25, 2020, the Board of Directors of Rafael Pharmaceuticals extended the expiration date of the Warrant held by Pharma Holdings to purchase shares of the Warrant from December 31, 2020 to June 30, 2021 and on August 31, 2020 the Board of Directors of Rafael Pharmaceuticals further extended the expiration date of the Warrant held by Pharma Holdings, LLC to purchase shares of the Warrant to August 15, 2021. Pharma Holdings also holds certain governance rights in Rafael Pharmaceuticals including appointment of directors. CS Pharma holds 16.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock. CS Pharma owned a $10 million Series D Convertible Note, with 3.5% interest, in Rafael Pharmaceuticals which was converted in January 2019. The Company and its subsidiaries collectively own securities representing 51% of the outstanding capital stock of Rafael Pharmaceuticals and 37% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant). The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution or winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class. The Company serves as the managing member of Pharma Holdings, and Pharma Holdings serves as the managing member of CS Pharma, with broad authority to make all key decisions regarding their respective holdings. Any distributions that are made to CS Pharma from Rafael Pharmaceuticals that are in turn distributed by CS Pharma, will need to be made pro rata to all members, which would entitle Pharma Holdings to 50% (based on current ownership) of such distributions. Similarly, if Pharma Holdings were to distribute proceeds it receives from CS Pharma, it would do so on a pro rata basis, entitling the Company to 90% (based on current ownership) of such distributions. The Company evaluated its investments in Rafael Pharmaceuticals in accordance with ASC 323, Investments - Equity Method and Joint Ventures, to establish the appropriate accounting treatment for its investment and has concluded that its investment did not meet the criteria for the equity method of accounting or consolidation and is carried at cost. Rafael Pharmaceuticals is a VIE; however, the Company has determined that it is not the primary beneficiary as it does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals’ economic performance. In addition, the interests held in Rafael Pharmaceuticals are Series D Convertible Preferred Stock and do not represent in-substance common stock. Howard Jonas has additional contractual rights to receive additional Rafael Pharmaceuticals shares (“Bonus Shares”) for an additional 10% of the fully diluted capital stock of Rafael Pharmaceuticals upon the achievement of certain milestones. The additional 10% is based on the fully diluted capital stock of Rafael Pharmaceuticals, excluding the remainder for the Warrant, at the time of issuance. If any of the milestones are met, the Bonus Shares are to be issued without any additional payment. Howard Jonas has the right to transfer the Bonus Shares, in his discretion, to others, including those who are instrumental to the future success of Rafael Pharmaceuticals. The Company holds a Warrant to purchase a significant stake in Rafael Pharmaceuticals, as well as other equity and governance rights in Rafael Pharmaceuticals. As of October 31, 2020, the Company owned 51% of the issued and outstanding equity in Rafael Pharmaceuticals. At that date, approximately 8% of the issued and outstanding equity was owned by the Company’s subsidiary CS Pharma and 42% was held by the Company’s subsidiary Pharma Holdings. The Company’s subsidiary Pharma Holdings holds a non-dilutive option to increase the Company’s total ownership to 56%. Based on the shares issued and outstanding of Rafael Pharmaceuticals as of October 31, 2020, the Company, and the Company’s affiliates, would need to pay approximately $16 million to exercise the Warrant in full. On an as-converted fully diluted basis (for all convertible securities of Rafael Pharmaceuticals outstanding), the Company, and the Company’s affiliates would need to pay approximately $104 million to exercise the Warrant in full. including additional issuances under the Line of Credit. Howard Jonas holds 10% of the interest in Pharma Holdings and would need to contribute 10% of any cash necessary to exercise any additional portion of the Warrant. Following any exercise, a portion of the Company’s interest in Rafael Pharmaceuticals would continue to be held for the benefit of the other equity holders in Pharma Holdings and CS Pharma. Given the Company’s anticipated available cash, the Company would not be able to exercise the Warrant in its entirety and the Company may never be able to exercise the Warrant in full. Rafael Pharmaceuticals may also issue additional equity interests, such as stock options, which will require the Company to pay additional cash to maintain the Company’s ownership percentage or exercise the Warrant in full.

0.90 0.50 0.45 0.10 Pharma Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase ownership to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share 16700000

10000000

0.035

0.51 0.37 The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution or winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class. 0.50 0.90 0.10 0.10 the Company owned 51% of the issued and outstanding equity in Rafael Pharmaceuticals. At that date, approximately 8% of the issued and outstanding equity was owned by the Company’s subsidiary CS Pharma and 42% was held by the Company’s subsidiary Pharma Holdings. The Company’s subsidiary Pharma Holdings holds a non-dilutive option to increase the Company’s total ownership to 56%. Based on the shares issued and outstanding of Rafael Pharmaceuticals as of October 31, 2020, the Company, and the Company’s affiliates, would need to pay approximately $16 million to exercise the Warrant in full. On an as-converted fully diluted basis (for all convertible securities of Rafael Pharmaceuticals outstanding), the Company, and the Company’s affiliates would need to pay approximately $104 million to exercise the Warrant in full. including additional issuances under the Line of Credit. Howard Jonas holds 10% of the interest in Pharma Holdings and would need to contribute 10% of any cash necessary to exercise any additional portion of the Warrant. NOTE 4 – INVESTMENT IN ALTIRA The Company entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) on May 13, 2020 with a member (the “Seller”) of Altira Capital & Consulting, LLC (“Altira”). Pursuant to the Purchase Agreement, on May 13, 2020, the Seller sold the economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive a 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceutical) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the membership interest consists of 1) $1,000,000 payable monthly in four equal installments of $250,000 each; 2) $3,000,000 due on January 3, 2021; 3) $3,000,000 due within fifteen (15) days of interim data analysis in Rafael Pharmaceuticals’ Phase 3 pivotal trial (AVENGER 500®) of CPI-613® (devimistat); and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement. The post-closing payments are to be made, at the Company’s discretion, in cash or shares of the Company’s Class B common stock based on the ten days average share price of the Company’s Class B common stock prior to the date of payment or any combination thereof. The Company has accounted for the purchase of the 33.333% membership interest in Altira as an equity method investment in accordance with the guidance in ASC 323, Investments – Equity Method and Joint Ventures. The Company determined that a 33.333% membership interest in Altira indicates that the Company is able to exercise significant influence over Altira, and the Company’s membership interest is considered to be “more than minor” in accordance with the guidance. The cost of the investment was determined to be $4,000,000 pursuant to the terms of the Purchase Agreement. The contingent consideration, as described within the Purchase Agreement, in the amount of $6,000,000, will be recognized when the payments are considered probable. For the year ended July 31, 2020, the Company determined that the investment in Altira was fully impaired and recorded an impairment charge of $4,000,000, which was the total amount of the investment in Altira. During the three months ended October 31, 2020, the Company did not make any payments to the Seller, and the remaining payments due to the Seller of $3,500,000 are recorded as a current liability. The assets and operations of Altira are not significant, and the Company has identified the equity investment in Altira as a related party transaction (see Note 11). the Seller sold the economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive a 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceutical) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the membership interest consists of 1) $1,000,000 payable monthly in four equal installments of $250,000 each; 2) $3,000,000 due on January 3, 2021; 3) $3,000,000 due within fifteen (15) days of interim data analysis in Rafael Pharmaceuticals’ Phase 3 pivotal trial (AVENGER 500®) of CPI-613® (devimistat); and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement. The post-closing payments are to be made, at the Company’s discretion, in cash or shares of the Company’s Class B common stock based on the ten days average share price of the Company’s Class B common stock prior to the date of payment or any combination thereof. 0.33333

4000000

6000000

4000000

3500000

NOTE 5 – INVESTMENT IN RP FINANCE, LLC On February 3, 2020, Rafael Pharmaceuticals entered into a Line of Credit Loan Agreement (“Line of Credit Agreement”) with RP Finance which provides a revolving commitment of up to $50,000,000 to fund clinical trials and other capital needs. The Company owns 37.5% of the equity interests in RP Finance and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. Howard Jonas owns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. The remaining 25% equity interests in RP Finance is owned by other shareholders of Rafael Pharmaceuticals. Under the Line of Credit Agreement, all funds borrowed will bear interest at the mid-term Applicable Federal Rate published by the U.S. Internal Revenue Service. The maturity date is the earlier of February 3, 2025, upon a change of control of Rafael Pharmaceuticals or a sale of Rafael Pharmaceuticals or its assets. Rafael Pharmaceuticals can draw on the facility on 60 days’ notice. The funds borrowed under the Line of Credit Agreement must be repaid out of certain proceeds from equity sales by Rafael Pharmaceuticals. In connection with entering into the Line of Credit Agreement, Rafael Pharmaceuticals agreed to issue to RP Finance shares of its common stock representing 12% of the issued and outstanding shares of Rafael Pharmaceuticals common stock, with such interest subject to anti-dilution protection as set forth in the Line of Credit Agreement. RP Finance has been identified as a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of RP Finance that most significantly impact RP Finance’s economic performance and, therefore, is not required to consolidate RP Finance. Therefore, we will use the equity method of accounting to record our investment in RP Finance. The Company has recognized approximately $96 thousand and $0 in income from its ownership interests of 37.5% in RP Finance for the three months ended October 31, 2020 and 2019, respectively. The assets and operations of RP Finance are not significant and the Company has identified the equity investment in RP Finance as a related party transaction (see Note 11). In August 2020, Rafael Pharmaceuticals called for a $5,000,000 draw on the line of credit facility and the facility was funded by RP Finance LLC in the amount $5 million, in August 2020 and September 2020. For the three months ended October 31, 2020, the Company funded $1,875,000 in accordance with its 37.5% ownership interests in RP Finance.

50000000

0.12

96000

0.375

Rafael Pharmaceuticals called for a $5,000,000 draw on the line of credit facility

5000000

1875000

NOTE 6 – INVESTMENT IN LIPOMEDIX PHARMACEUTICALS LTD. LipoMedix is a development-stage, privately held Israeli company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery. As of October 31, 2020, the Company held 68% of the issued and outstanding ordinary shares of LipoMedix and has consolidated this investment from the second quarter of fiscal 2018. In November 2019, the Company provided bridge financing in the principal amount of $100,000 to LipoMedix with a maturity date of May 3, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets. In January 2020, the Company provided bridge financing in the principal amount of $125,000 to LipoMedix with a maturity date of May 3, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets. In March 2020, the Company provided bridge financing in the principal amount of $75,000 to LipoMedix with a maturity date of April 20, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets. On May 20, 2020, the Company entered into a Share Purchase Agreement with LipoMedix to purchase 4,000,000 ordinary shares of LipoMedix for an aggregate purchase price of $1,000,000. The purchase consideration consisted of the outstanding Promissory Notes between the Company and LipoMedix dated November 13, 2019, January 21, 2020 and March 27, 2020 in the total principal amount of $300,000 plus accrued interest, for an aggregate amount of $306,737, and $693,263 of cash, thereby increasing the Company’s ownership in Lipomedix from 58% to 68%.

0.68

100000

125000

75000

4000000

1000000

300000

306737

693263

0.58

0.68

NOTE 7 – FAIR VALUE MEASUREMENTS Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value: <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"></td><td style="font-family: Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font-family: Times New Roman, Times, Serif; text-align: justify">Level 1 - quoted prices in active markets for identical assets or liabilities;</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"></td><td style="font-family: Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font-family: Times New Roman, Times, Serif; text-align: justify">Level 2 - quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"></td><td style="font-family: Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font-family: Times New Roman, Times, Serif; text-align: justify">Level 3 - unobservable inputs for the asset or liability, such as discounted cash flow models or valuations.</td></tr></table> The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following is a listing of the Company’s assets required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of October 31, 2020 and July 31, 2020: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value at October 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-style: italic"> </td> <td colspan="14" style="white-space: nowrap; font-style: italic; text-align: center">(unaudited, in thousands)</td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">Assets:</td><td style="font-style: italic"> </td> <td colspan="14" style="white-space: nowrap; font-style: italic; text-align: center"> </td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Hedge Funds</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,454</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,454</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,454</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,454</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value at July 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-style: italic"> </td> <td colspan="14" style="white-space: nowrap; font-style: italic; text-align: center">(in thousands)</td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">Assets:</td><td style="font-style: italic"> </td> <td colspan="14" style="white-space: nowrap; font-style: italic; text-align: center"> </td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Hedge Funds</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">7,510</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">7,510</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,510</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,510</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> At October 31, 2020 and July 31, 2020, the Company did not have any liabilities measured at fair value on a recurring basis. The following table summarizes the changes in the fair value of the assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3): <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">October 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">October 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="6" style="white-space: nowrap; text-align: center">(unaudited, in thousands)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Balance, beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,510</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,125</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Liquidation of Hedge Fund Investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total gain (loss) included in earnings</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">944</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Balance, end of period</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,454</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,088</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Hedge funds classified as Level 3 include investments and securities which may not be based on readily observable data inputs. The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. The fair value of these assets is estimated based on information provided by the fund managers or the general partners. Therefore, these assets are classified as Level 3. In October 2020, the Company received a $2 million distribution of the Company’s investments in Hedge Funds. The Company holds $2.0 million in investments in securities in another entity that are not liquid, which were included in Investments - Other Pharmaceuticals in the accompanying consolidated balance sheets. The investment is accounted for under ASC 321, Investments - Equity Securities, using the measurement alternative as defined within the guidance, and the Company recorded an impairment loss of $0.7 million and $0 for the three months ended October 31, 2020 and 2019, respectively. Fair Value of Other Financial Instruments The estimated fair value of the Company’s other financial instruments was determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting these data to develop estimates of fair value. Consequently, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. Cash and cash equivalents, prepaid expense and other current assets, and accounts payable. At October 31, 2020 and July 31, 2020, the carrying amount of these assets and liabilities approximated fair value because of the short period of time to maturity. The fair value estimates for cash and cash equivalents were classified as Level 1 and other current assets, and other current liabilities were classified as Level 2 of the fair value hierarchy. Other assets and other liabilities. At October 31, 2020 and July 31, 2020, the carrying amount of these assets and liabilities approximated fair value. The fair values were estimated based on the Company’s assumptions, which were classified as Level 3 of the fair value hierarchy. The Company’s financial instruments include trade accounts receivable, trade accounts payable, and due from related parties. The recorded carrying amounts of trade accounts receivable, trade accounts payable and due from related parties approximate their fair value due to their short-term nature. Other than noted above, the Company did not have any other assets or liabilities that were measured at fair value on a recurring basis as of October 31, 2020 or July 31, 2020.

2000000

700000

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value at October 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-style: italic"> </td> <td colspan="14" style="white-space: nowrap; font-style: italic; text-align: center">(unaudited, in thousands)</td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">Assets:</td><td style="font-style: italic"> </td> <td colspan="14" style="white-space: nowrap; font-style: italic; text-align: center"> </td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Hedge Funds</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,454</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,454</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,454</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,454</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value at July 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-style: italic"> </td> <td colspan="14" style="white-space: nowrap; font-style: italic; text-align: center">(in thousands)</td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">Assets:</td><td style="font-style: italic"> </td> <td colspan="14" style="white-space: nowrap; font-style: italic; text-align: center"> </td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Hedge Funds</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">7,510</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">7,510</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,510</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,510</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

6454000 6454000

6454000

7510000 7510000

7510000

5125000

-2000000

944000

-37000

6454000

5088000

NOTE 8 – TRADE ACCOUNTS RECEIVABLE Trade Accounts Receivable consisted of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">October 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">July 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-style: italic"> </td> <td colspan="2" style="font-style: italic; text-align: center">(unaudited, in thousands)</td><td style="font-style: italic"> </td><td style="font-style: italic"> </td> <td colspan="2" style="font-style: italic; text-align: center">(in thousands)</td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Trade Accounts Receivable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">415</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">364</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accounts Receivable - Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">121</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less Allowance for Doubtful Accounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(256</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(218</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Trade Accounts Receivable, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">309</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">267</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The current portion of deferred rental income included in prepaid expenses and other current assets was approximately $77 thousand and $11 thousand as of October 31, 2020 and July 31, 2020, respectively. The noncurrent portion of deferred rental income included in Other Assets was approximately $1.5 million as of October 31, 2020 and July 31, 2020.

77000

11000

1500000

415000

364000

150000

121000

256000

218000

309000

267000

NOTE 9 – PROPERTY AND EQUIPMENT Property and equipment consisted of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">October 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">July 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-style: italic"> </td> <td colspan="2" style="font-style: italic; text-align: center">(unaudited, in thousands)</td><td style="font-style: italic"> </td><td style="font-style: italic"> </td> <td colspan="2" style="font-style: italic; text-align: center">(in thousands)</td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Building and Improvements</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47,736</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47,591</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Land</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,412</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,412</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Furniture and Fixtures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,145</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,145</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">256</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">256</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,549</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,404</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Less Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,408</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,971</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">44,141</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">44,433</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Other property and equipment consist of other equipment and miscellaneous computer hardware.  Depreciation expense pertaining to property and equipment was approximately $0.4 million and $0.5 million for the three months ended October 31, 2020 and 2019, respectively.  The Company’s headquarters are located at 520 Broad Street in Newark, New Jersey where it occupies office space in the building owned by its subsidiary. In August 2020, the Company sold an office/data center building in Piscataway, New Jersey, which was classified as held for sale at July 31, 2020.

400000

500000

47736000

47591000

10412000

1145000

256000

59549000

59404000

15408000

14971000

44141000

44433000

NOTE 10 – LOSS PER SHARE Basic net loss per share is computed by dividing net loss attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted loss per shares includes potentially dilutive securities such as stock options and other convertible instruments. These securities have been excluded from the calculation of diluted net loss per shares for the three months ended October 31, 2020 and 2019 because all such securities are anti-dilutive for all periods presented. The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended October 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 2.65pt">Stock Options</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">571,800</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">586,874</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; padding-left: 2.65pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">571,800</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">586,874</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The diluted loss per share computation equals basic loss per share for the three months ended October 31, 2020 and 2019 because the Company had a net loss and the impact of the assumed exercise of stock options would have been anti-dilutive.

571800 586874 571800 586874

NOTE 11 – RELATED PARTY TRANSACTIONS The Company has historically maintained an intercompany balance due to/from related parties that relates to cash advances for investments, loan repayments, charges for services provided to the Company by IDT Corporation, or IDT, and payroll costs for the Company’s personnel that were paid by IDT. The Company also receives rental income from various companies under common control to IDT. The Company recorded expense of approximately $66 thousand in related party services to IDT, of which approximately $30 thousand is included in due to related parties at October 31, 2020. IDT leases approximately 80,000 square feet of office space plus parking occupied by IDT at 520 Broad Street, Newark, NJ and approximately 3,600 square feet of office space in Jerusalem, Israel. IDT paid the Company approximately $459 thousand for office rent and parking during the three months ended October 31, 2020 and 2019.  As of October 31, 2020 and 2019, IDT owed the Company approximately $69 thousand and $0, respectively, for office rent and parking. The Company leases space to related parties which represented approximately 56% and 43% of the Company’s total revenue for the three months ended October 31, 2020 and 2019, respectively. See Note 16 for future minimum rent payments from related parties and other tenants. The Company provides Rafael Pharmaceuticals with administrative, finance, accounting, tax and legal services. Howard S. Jonas serves as a Chairman of the Board of Rafael Pharmaceuticals and owns an equity interest in Rafael Pharmaceuticals. The Company billed Rafael Pharmaceuticals $120,000 for the three months ended October 31, 2020 and 2019, respectively. As of October 31, 2020 and July 31, 2020, Rafael Pharmaceuticals owed the Company $240,000 and $120,000, respectively, included in due from Rafael Pharmaceuticals. In September 2018, CS Pharma, in which the Company owns an effective 45% interest, exercised a warrant to purchase 8 million shares of Rafael Pharmaceuticals’ Series D Convertible Preferred Stock for $10 million representing approximately 8% of the equity on a fully-diluted basis (excluding the remainder of the Warrant) of Rafael Pharmaceuticals. The Warrant in full is exercisable for up to 56% of the fully diluted equity of Rafael Pharmaceuticals. The right to exercise the first $10 million of the Warrant was held by CS Pharma. CS Pharma is owned by 0.25% by Michael Weiss, a non-employee director of the Company. The remainder of the Warrant is held by Pharma Holdings. On November 5, 2018, Pharma Holdings, LLC partially exercised a warrant to purchase 4 million shares of Rafael Pharmaceuticals’ Series D Convertible Preferred Stock for $5 million, of which $500,000 was contributed by Howard Jonas. On November 15, 2018, Howard Jonas entered into an agreement to purchase a convertible note from the Company for $15.0 million convertible into shares of Class B common stock at $8.47 per share. The term of the note was three years with interest on the principal amount at a rate of 6% per annum, compounded quarterly. At issuance, the Company recorded a debt discount of approximately $70,000 related to the beneficial conversion feature of the note and amortized approximately $16,000 of the discount in fiscal 2020 which was recorded as interest expense. In addition, the Company recorded approximately $650,000 of interest expense for the three months ended October 31, 2020 and 2019. In August 2019, the note including accrued interest of approximately $667,000 was converted into 1,849,749 shares of common stock. On January 10, 2019, Pharma Holdings partially exercised a warrant to purchase 5.1 million shares of Series D Convertible Preferred Stock of Rafael Pharmaceuticals for $6.4 million, of which $640,000 was contributed by Howard Jonas. On January 23, 2019, Pharma Holdings partially exercised a warrant to purchase 36.3 million shares of Series D Convertible Preferred Stock of Rafael Pharmaceuticals for $34.4 million, of which $3.4 million was contributed by Howard Jonas. On January 29, 2020, in connection with the vesting of certain restricted shares of Class B common stock held by an officer of the Company, the Company withheld 5,238 shares to pay for the payroll taxes on the officer’s behalf, totaling approximately $116,000. The Company acquired membership interest in Altira, a related party in fiscal 2020 and fiscal 2021 (see Note 4 and Note 17). The Company recognized approximately $96 thousand and $0 in income from its ownership interests of 37.5% in RP Finance for the three months ended October 31, 2020 and 2019, respectively (see Note 5).

66000

30000

80000

3600

459000

69000

0.56 0.43

120000

240000

120000

4000000

5000000

500000

the Company for $15.0 million convertible into shares of Class B common stock at $8.47 per share. The term of the note was three years with interest on the principal amount at a rate of 6% per annum, compounded quarterly. At issuance, the Company recorded a debt discount of approximately $70,000 related to the beneficial conversion feature of the note and amortized approximately $16,000 of the discount in fiscal 2020 which was recorded as interest expense. In addition, the Company recorded approximately $650,000 of interest expense for the three months ended October 31, 2020 and 2019. In August 2019, the note including accrued interest of approximately $667,000 was converted into 1,849,749 shares of common stock.

5100000

6400000

640000

36300000

34400000

3400000

5238

116000

The Company recognized approximately $96 thousand and $0 in income from its ownership interests of 37.5% in RP Finance for the three months ended October 31, 2020 and 2019, respectively (see Note 5).

NOTE 12 – INCOME TAXES The Company has completed its accounting for the income tax effects of the enactment of the Tax Act and Care Act. At October 31, 2020, the Company has federal net operating loss (“NOL”) carryforwards from domestic operations of approximately $34.4 million, to offset future taxable income. The Company has state NOLs of $15.3 million. The Company has NOLs from foreign operations of $2.3 million. As part of the Tax Act, federal NOLs generated in 2018 and later are not subject to an expiration period and are available to offset 80% of taxable income in the year in which they are utilized. The federal NOL carryforwards generated prior to 2018 will begin to expire in 2026. The state NOLs will begin to expire in 2038 and foreign NOLs do not expire. The Company anticipates that its assumptions and estimates may change as a result of future guidance and interpretation from the Internal Revenue Service, the SEC, the FASB, and various other taxing jurisdictions. In particular, the Company anticipates that the U.S. state jurisdictions will continue to determine and announce their conformity with or decoupling from the Tax Act, either in its entirety or with respect to specific provisions. Legislative and interpretive actions could result in adjustments to the Company’s balances.

34400000

15300000

2300000

0.80

NOTE 13 – BUSINESS SEGMENT INFORMATION The Company conducts business as two operating segments, Pharmaceuticals and Real Estate. The Company’s reportable segments are distinguished by types of service, customers and methods used to provide their services. The operating results of these business segments are regularly reviewed by the Company’s CEO and chief operating decision-maker. The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Pharmaceuticals segment based primarily on research and development efforts and results of clinical trials and the Real Estate segment based primarily on results of operations. All investments in Rafael Pharmaceuticals and assets and expenses associated with LipoMedix and Barer are tracked separately in the Pharmaceuticals segment. All corporate costs are allocated to the Real Estate segment. The Pharmaceuticals segment is comprised of preferred and common equity interests and the Warrant to purchase equity interests in Rafael Pharmaceuticals, a majority equity interest in LipoMedix and Barer. To date, the Pharmaceuticals segment has not generated any revenues. The Real Estate segment consists of the Company’s real estate holdings, including a building at 520 Broad Street in Newark, New Jersey that houses headquarters for the Company and certain affiliates and its associated public garage and a portion of an office building in Israel. In August 2020, the Company sold a 3-story, 65,253 square foot office building located at 225 Old New Brunswick Road in Piscataway, New Jersey to 225 ONBR, LLC, an entity unaffiliated with the Company. The purchase price was $3,875,000 and, after transfer taxes and broker’s commission, the Company received $3,675,638 in cash. As of July 31, 2020, the building was classified as held for sale on the consolidated balance sheet. Operating results for the business segments of the Company are as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-style: italic; border-bottom: Black 1.5pt solid">(unaudited, in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pharmaceuticals</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Real Estate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">Three Months Ended October 31, 2020</td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Revenues</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,053</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,053</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Loss from operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(533</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,958</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,491</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Three Months Ended October 31, 2019</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenues</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,210</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Loss from operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(266</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,276</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,542</td><td style="text-align: left">)</td></tr> </table> Geographic Information Revenues from tenants located outside of the United States were generated entirely from related parties located in Israel. Revenues from these non-United States customers as a percentage of total revenues were as follows (revenues by country are determined based on the location of the related facility): <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Three Months Ended October 31, (unaudited)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Revenue from tenants located in Israel</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">%</td></tr> </table> Net long-lived assets and total assets held outside of the United States, which are located in Israel, were as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid">(unaudited, in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">United States</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Israel</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">October 31, 2020</td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Long-lived assets, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">42,564</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,141</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,744</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,874</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,618</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">July 31, 2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Long-lived assets, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">42,840</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,593</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">44,433</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">132,286</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,061</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">136,347</td><td style="text-align: left"> </td></tr> </table>

the Company sold a 3-story, 65,253 square foot office building located at 225 Old New Brunswick Road in Piscataway, New Jersey to 225 ONBR, LLC, an entity unaffiliated with the Company. The purchase price was $3,875,000 and, after transfer taxes and broker’s commission, the Company received $3,675,638 in cash.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-style: italic; border-bottom: Black 1.5pt solid">(unaudited, in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pharmaceuticals</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Real Estate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">Three Months Ended October 31, 2020</td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Revenues</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,053</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,053</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Loss from operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(533</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,958</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,491</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Three Months Ended October 31, 2019</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenues</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,210</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Loss from operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(266</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,276</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,542</td><td style="text-align: left">)</td></tr> </table>

1053000

-533000 -1958000 -2491000

1210000

-266000 -1276000 -1542000

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Three Months Ended October 31, (unaudited)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Revenue from tenants located in Israel</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">%</td></tr> </table>

0.06

0.05

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid">(unaudited, in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">United States</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Israel</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">October 31, 2020</td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Long-lived assets, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">42,564</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,141</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,744</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,874</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,618</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">July 31, 2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Long-lived assets, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">42,840</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,593</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">44,433</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">132,286</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,061</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">136,347</td><td style="text-align: left"> </td></tr> </table>

42564000

1577000

44141000

130744000

3874000

134618000

42840000

1593000

44433000

132286000

4061000

136347000

NOTE 14 – COMMITMENTS AND CONTINGENCIES Legal Proceedings On September 17, 2018, LipoMedix was notified of a claim initiated by one of its founders seeking payment of consulting fees in the amount of approximately $377,000 and seeking to place restrictions on LipoMedix’s bank accounts and other assets to protect his claim. LipoMedix did not believe that the individual had the right to receive any payment at that time. LipoMedix responded to the demand for the placement of restrictions on its assets. In May 2019, LipoMedix received a letter from the other founder requesting payment of his consulting fees. On July 15, 2019, the parties settled the matters and the two founders will be paid a percentage of future investments and certain other proceeds. On July 12, 2019, the Company received a Citation and Notification of Penalty from the Occupational Safety and Health Administration of the U.S. Department of Labor, or OSHA, related to an OSHA inspection of 520 Broad Street, Newark, New Jersey. The citation seeks to impose penalties related to alleged violations of the Occupation Safety and Health Act of 1970 at 520 Broad Street. On July 31, 2019, the Company filed a Notice of Contest with OSHA contesting the citation in its entirety. On February 14, 2020, the Company entered into a Settlement Agreement with OSHA, as related to the citation received on July 12, 2019. As part of the Settlement Agreement, the Company agreed to pay a penalty of $127,294 in eight quarterly installment payments through November 2021. The Company accounts for contingencies when a loss is considered probable and can be reasonably estimated. For the matters disclosed above, a legal accrual for approximately $64,000 has been recorded for legal fees and losses believed to be both probable and reasonably estimable, but an exposure to additional loss may exist in excess of the amount accrued. On December 31, 2019, an employee of the Company filed a complaint in connection with the incident that led to the OSHA inspection noted above for personal injuries against the Company and other parties in the New Jersey Supreme Court for an incident that took place on January 31, 2019 at 520 Broad Street, Newark, New Jersey. The Company intends to vigorously defend this matter. The loss is considered remote and no accrual has been recorded. The Company may from time to time be subject to legal proceedings that may arise in the ordinary course of business. Although there can be no assurance in this regard, other than noted above, the Company does not expect any of those legal proceedings to have a material adverse effect on the Company’s results of operations, cash flows or financial condition.

377000

As part of the Settlement Agreement, the Company agreed to pay a penalty of $127,294 in eight quarterly installment payments through November 2021.

64000

NOTE 15 – EQUITY On November 15, 2018, Howard Jonas entered into an agreement to purchase a convertible note from the Company for $15.0 million that was convertible into shares of Class B common stock at $8.47 per share. The term of the note was three years with interest on the principal amount at a rate of 6% per annum, compounded quarterly. In August 2019, the note, including interest of approximately $667,000 was converted into 1,849,749 shares of Class B common stock. Pursuant to the Company’s 2018 Equity Incentive Plan, each of our three non-employee directors of the Company was granted 4,203 restricted shares of our Class B common stock in January 2020 which fully vested on the date of the grant. The fair value of the awards on the date of the grant was approximately $208,000 which was included in selling, general and administrative expense. During the three months ended October 31, 2020, 8,750 options were exercised. At October 31, 2020, there was no unrecognized compensation cost related to non-vested stock options. Stock Options A summary of stock option activity for the Company is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Term (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value (in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding at July 31, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">580,874</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.90</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.65</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,846</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,750</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Cancelled / Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(324</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Outstanding at October 31, 2020</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">571,800</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4.90</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,802</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 1.5pt">Exercisable at October 31, 2020</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">571,800</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4.90</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,802</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> Restricted Stock The fair value of restricted shares of the Company’s Class B common stock is determined based on the closing price of the Company’s Class B common stock on the grant date. Share awards generally vest on a graded basis over three years of service. A summary of the status of the Company’s grants of restricted shares of Class B common stock is presented below: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Non-vested Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Outstanding at July 31, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">123,104</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10.80</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,360</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16.58</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,027</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(16.91</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Cancelled / Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,099</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13.54</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt">Non-vested shares at October 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">123,338</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13.79</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> At October 31, 2020, there was $1.4 million of total unrecognized compensation cost related to non-vested stock-based compensation arrangements, which is expected to be recognized over the next 2.18 years.

15000000

8.47

P3Y

0.06

667000

1849749

4203

208000 8750

P3Y

1400000

P2Y65D

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Term (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value (in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding at July 31, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">580,874</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.90</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.65</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,846</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,750</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Cancelled / Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(324</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Outstanding at October 31, 2020</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">571,800</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4.90</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,802</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 1.5pt">Exercisable at October 31, 2020</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">571,800</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4.90</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,802</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

580874

4.90

P2Y237D

2846000

4.90

324

571800

4.90

P2Y146D

2802000

571800

4.90

P2Y146D

2802000

123104

10.80

9360

16.58

7027

-16.91

2099

13.54

123338

13.79

NOTE 16 – LEASES The Company is the lessor of certain properties which are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2029. Lease income included on the consolidated statements of operations and comprehensive loss for the three months ended October 31, 2020 and 2019 was $634 thousand and $866 thousand, respectively. The future contractual minimum lease payments to be received (excluding operating expense reimbursements) by the Company as of October 31, 2020, under non-cancellable operating leases which expire on various dates through 2028 are as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Year ending July 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Related Parties</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"> </td><td style="font-style: italic"> </td> <td colspan="10" style="white-space: nowrap; font-style: italic; text-align: center">(in thousands)</td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 64%">2021 (remaining)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,532</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">603</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,135</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,078</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">776</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,854</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,117</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">592</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,709</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">538</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,693</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,659</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,209</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,948</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,948</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total Minimum Future Rental Income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,541</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,007</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,548</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> The Company has related party leases that expire in April 2025 for (i) an aggregate of 88,631 square feet, which includes two parking spots per thousand square feet of space leased at 520 Broad Street, Newark, New Jersey, and (ii) 3,595 square feet in Israel. The annual rent is approximately $2.0 million in the aggregate. The related parties have the right to terminate the domestic leases upon four months’ notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months’ notice. IDT has the right to lease an additional 50,000 square feet, in 25,000-foot increments, in the building located at 520 Broad Street, Newark, New Jersey on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.

The Company is the lessor of certain properties which are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2029.

634000

866000

2000000

The related parties have the right to terminate the domestic leases upon four months’ notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months’ notice. IDT has the right to lease an additional 50,000 square feet, in 25,000-foot increments, in the building located at 520 Broad Street, Newark, New Jersey on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Year ending July 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Related Parties</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"> </td><td style="font-style: italic"> </td> <td colspan="10" style="white-space: nowrap; font-style: italic; text-align: center">(in thousands)</td><td style="font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 64%">2021 (remaining)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,532</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">603</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,135</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,078</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">776</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,854</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,117</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">592</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,709</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">538</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,693</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,659</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,209</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,948</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,948</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total Minimum Future Rental Income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,541</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,007</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,548</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

1532

603

2135

2078

776

2854

2117

592

2709

2155

538

2693

1659

550

2209

1948

9541

5007

14548

NOTE 17 – SUBSEQUENT EVENTS In November 2020, Rafael Pharmaceuticals called for a $5 million draw on the line of credit facility and the facility was funded by RP Finance in the amount of $5 million. The Company funded $1.875 million of the $5 million draw in accordance with its 37.5% ownership interests in RP Finance. The Company entered into a Membership Interest Purchase Agreement (the “Second Altira Agreement”) on December 7, 2020 with a member (the “Seller”) of Altira. Pursuant to the Second Altira Agreement, on December 7, 2020, the Seller sold the economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive a 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceuticals) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the membership interest consists of 1) $1,000,000 payable monthly in four equal installments of $250,000 each, commencing on January 4, 2021; 2) $3,000,000 due on January 4, 2021; 3) $3,000,000 due within fifteen (15) days of the earlier to occur of either the completion of Rafael Pharmaceuticals’ Phase III pivotal trial (AVENGER 500®) of CPI-613® (devimistat) or May 31, 2021 and not before January 4, 2021; and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement. Certain of the post-closing payments may be made, at the Company’s discretion, in cash or shares of the Company’s Class B common stock based on the ten day average share price of the Company’s Class B common stock prior to the date of payment or any combination thereof. On December 7, 2020, Rafael Holdings entered into a Securities Purchase Agreement (the “SPA”) for the sale of 567,437 shares of the Company’s Class B common stock at a price per share of $22.91 (which was the closing price for the Class B common stock on the New York Stock Exchange on December 4, 2020 the trading day immediately preceding the date of the SPA) for an aggregate purchase price of $13 million. In connection with the purchases, each purchaser was granted warrants to purchase twenty percent (20%) of the shares of Class B common stock purchased by such purchaser. The warrants have an exercise price of $22.91 per share and expire on June 6, 2022. The Company issued warrants to purchase an aggregate of 113,487 shares of Class B common stock. A majority of the proceeds received pursuant to the SPA are expected to be used by the Company to exercise an additional portion of the warrant held by the Company’s subsidiary to purchase equity securities of Rafael Pharmaceuticals, Inc. in order to maintain the Company’s relative position as a percentage of shares outstanding as well as the fully-diluted equity of Rafael Pharmaceuticals in light of issuances of Rafael Pharmaceuticals equity securities to third-party shareholders of Rafael Pharmaceuticals, including due to warrant exercises by these shareholders. The Company intends to use additional proceeds to fund the operations of its drug development programs including its Barer Institute subsidiary, and for general corporate purposes. Under the SPA, two entities, on whose Boards of Directors Howard Jonas, the Registrant’s Chief Executive Officer and Chairman of the Board serves, each purchased 218,245 shares of Class B common stock for consideration of $10 million. The shares and warrants were issued in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended. On December 10, 2020, a controlled subsidiary of the Company, Farber Partners LLC, or Farber, reached an agreement with Princeton University to in-license certain patents and related information related to the serine hydroxymethyltransferase (SHMT) inhibitor program developed by the laboratory of Dr. Joshua D. Rabinowitz at Princeton. Farber will pay Princeton a minimum annual royalty payment of $50 thousand, in addition to percentage royalties and a percentage of any sublicense revenue. Additionally, there are development milestone payments which Farber will pay Princeton for the first three products developed by Farber, or any sublicensees or affiliates.

In November 2020, Rafael Pharmaceuticals called for a $5 million draw on the line of credit facility and the facility was funded by RP Finance in the amount of $5 million. The Company funded $1.875 million of the $5 million draw in accordance with its 37.5% ownership interests in RP Finance. the Seller sold the economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive a 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceuticals) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the membership interest consists of 1) $1,000,000 payable monthly in four equal installments of $250,000 each, commencing on January 4, 2021; 2) $3,000,000 due on January 4, 2021; 3) $3,000,000 due within fifteen (15) days of the earlier to occur of either the completion of Rafael Pharmaceuticals’ Phase III pivotal trial (AVENGER 500®) of CPI-613® (devimistat) or May 31, 2021 and not before January 4, 2021; and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement.

567437

22.91

13000000 0.20

22.91

113487 218245

10000000

50000

EX-101.SCH 7 rfl-20201031.xsd XBRL SCHEMA FILE 001 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Alternate 0 link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Description of Business link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Investment in Rafael Pharmaceuticals link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Investment in Altira link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Investment in RP Finance, LLC link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Investment in LipoMedix Pharmaceuticals Ltd. link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Trade Accounts Receivable link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Loss per Share link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Business Segment Information link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Equity link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Description of Business (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Trade Accounts Receivable (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Loss per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Business Segment Information (Tables) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Description of Business (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Description of Business (Details) - Schedule of entities majority-owned subsidiaries link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Investment in Rafael Pharmaceuticals (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Investment in Altira (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Investment in RP Finance, LLC (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Investment in LipoMedix Pharmaceuticals Ltd. (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Fair Value Measurements (Details) - Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Fair Value Measurements (Details) - Schedule of assets measured at fair value on a recurring basis using significant unobservable inputs link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Trade Accounts Receivable (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Trade Accounts Receivable (Details) - Schedule of trade accounts receivable link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Loss per Share (Details) - Schedule of earning per share link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - Business Segment Information (Details) link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - Business Segment Information (Details) - Schedule of operating results for the business segments link:presentationLink link:definitionLink link:calculationLink 051 - Disclosure - Business Segment Information (Details) - Schedule of revenue from tenants by geographic areas link:presentationLink link:definitionLink link:calculationLink 052 - Disclosure - Business Segment Information (Details) - Schedule of net long-lived assets and total assets by geographic areas link:presentationLink link:definitionLink link:calculationLink 053 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 054 - Disclosure - Equity (Details) link:presentationLink link:definitionLink link:calculationLink 055 - Disclosure - Equity (Details) - Schedule of stock option activity link:presentationLink link:definitionLink link:calculationLink 056 - Disclosure - Equity (Details) - Schedule of grants of restricted shares of Class B common stock link:presentationLink link:definitionLink link:calculationLink 057 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 058 - Disclosure - Leases (Details) - Schedule of future contractual minimum lease payments link:presentationLink link:definitionLink link:calculationLink 059 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 rfl-20201031_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 rfl-20201031_def.xml XBRL DEFINITION FILE EX-101.LAB 10 rfl-20201031_lab.xml XBRL LABEL FILE Class of Stock [Axis] Statement of Financial Position [Abstract] Total current assets TOTAL ASSETS Total assets Total current liabilities TOTAL LIABILITIES Total equity attributable to Rafael Holdings, Inc. TOTAL EQUITY Balance Balance TOTAL LIABILITIES AND EQUITY Income Statement [Abstract] Total revenue Revenues Loss from operations Loss before income taxes Consolidated net loss Net loss Net loss attributable to Rafael Holdings, Inc. Total comprehensive loss Total comprehensive loss attributable to Rafael Holdings, Inc. Statement of Stockholders' Equity [Abstract] Balance (in Shares) Balance (in Shares) Equity Components [Axis] Statement of Cash Flows [Abstract] Net cash used in operating activities Net cash provided by (used in) investing activities Net cash provided by financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash and cash equivalents Accounting Policies [Abstract] Schedule of entities majority-owned subsidiaries [Abstract] Consolidated Entities [Axis] ASU 2016-01 Transition [Abstract] Investment In Acquired Royalty Rights [Abstract] Investment In RP Finance LLC [Abstract] Business Combinations [Abstract] Fair Value Disclosures [Abstract] Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy [Abstract] Fair Value Hierarchy and NAV [Axis] Schedule of assets measured at fair value on a recurring basis using significant unobservable inputs [Abstract] Balance, beginning of period Balance, end of period Receivables [Abstract] Schedule of trade accounts receivable [Abstract] Property, Plant and Equipment [Abstract] Schedule of property and equipment [Abstract] Asset Class [Axis] Earnings Per Share [Abstract] Schedule of earning per share [Abstract] Stock Options Total Related Party Transactions [Abstract] Income Tax Disclosure [Abstract] Segment Reporting [Abstract] Schedule of operating results for the business segments [Abstract] Segments [Axis] Collateral Held [Axis] Schedule of revenue from tenants by geographic areas [Abstract] Schedule of net long-lived assets and total assets by geographic areas [Abstract] Geographical [Axis] Commitments and Contingencies Disclosure [Abstract] Stockholders' Equity Note [Abstract] Schedule of stock option activity [Abstract] Number of Options, Outstanding, Beginning balance Number of Options, Outstanding, Ending balance Weighted Average Exercise Price, Outstanding, Beginning balance Weighted Average Exercise Price, Outstanding, Ending balance Aggregate Intrinsic Value, Outstanding, Beginning balance Aggregate Intrinsic Value, Outstanding, Ending balance Schedule of grants of restricted shares of Class B common stock [Abstract] Number of Non-vested Shares, Beginning Balance Number of Non-vested Shares, Ending Balance Weighted Average Grant Date Fair Value, Beginning balance Weighted Average Grant Date Fair Value, Ending balance Disclosure Text Block [Abstract] Schedule of future contractual minimum lease payments [Abstract] Total Minimum Future Rental Income Related Party Transaction [Axis] Subsequent Events [Abstract] Entity File Number Entity Current Reporting Status Entity Ex Transition Period Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Document Type Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Emerging Growth Company Entity Filer Category Entity Incorporation, State or Country Code Entity Interactive Data Current Entity Registrant Name Entity Shell Company Entity Small Business ASSETS CURRENT ASSETS Trade accounts receivable, net of allowance for doubtful accounts of $256 and $218 at October 31, 2020 and July 31, 2020, respectively Allowance for doubtful accounts (in Dollars) Due from Rafael Pharmaceuticals Prepaid expenses and other current assets Assets held for sale Property and equipment, net Total Equity investment – RP Finance Due from RP Finance LLC Investments – Rafael Pharmaceuticals Investments – Other Pharmaceuticals Investments – Hedge Funds Deferred income tax assets, net In-process research and development and patents Other assets LIABILITIES AND EQUITY CURRENT LIABILITIES Trade accounts payable Accrued expenses Amount due for purchase of membership interest Other current liabilities Due to related parties Other liabilities COMMITMENTS AND CONTINGENCIES EQUITY Common stock value Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Additional paid-in capital Accumulated deficit Accumulated other comprehensive income related to foreign currency translation adjustment Noncontrolling interests REVENUE Rental – Third Party Rental – Related Party Parking Other – Related Party COSTS AND EXPENSES Selling, general and administrative Research and development Depreciation and amortization Interest expense, net Net loss resulting from foreign exchange transactions Gain on sale of building Equity in earnings of RP Finance Equity in earnings of RP Finance Net loss (income) attributable to noncontrolling interests OTHER COMPREHENSIVE LOSS Foreign currency translation adjustment Loss per share Basic and diluted (in Dollars per share) Weighted average number of shares used in calculation of loss per share Basic and diluted (in Shares) Stock-based compensation Stock-based compensation (in Shares) Stock options exercised Stock options exercised (in Shares) Foreign currency translation adjustment Shares issued for convertible note Shares issued for convertible note (in Shares) Conversion of LipoMedix bridge notes Operating activities Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization Deferred income taxes Impairment of investments - Other Pharmaceuticals Impairment of investments - Other Pharmaceuticals Impairment charge Provision for doubtful accounts Stock-based compensation Amortization of debt discount Change in assets and liabilities: Accounts payable and accrued expenses Other current liabilities Due to related parties Other liabilities Investing activities Proceeds from sale of building Proceeds related to distribution of Hedge Funds Financing activities Proceeds from exercise of options Effect of exchange rate changes on cash and cash equivalents Supplemental schedule of noncash investing and financing activities Conversion of LipoMedix bridge notes Conversions of related party convertible notes payable and accrued interest Unrealized gain (loss) on investments - Hedge Funds Provision for income taxes Comprehensive loss attributable to noncontrolling interests Net unrealized (gain) loss on investments - Hedge Funds Gain on sale of building Trade accounts receivable Prepaid expenses and other current assets Other assets Due from Rafael Pharmaceuticals Due from Rafael Pharmaceuticals Purchases of property and equipment Payment to fund RP Finance EX-101.PRE 11 rfl-20201031_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Oct. 31, 2020	Dec. 14, 2020
Document Information Line Items
Entity Registrant Name	Rafael Holdings, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--07-31
Amendment Flag	false
Entity Central Index Key	0001713863
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Oct. 31, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity File Number	000-55863
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Class A common stock
Document Information Line Items
Entity Common Stock, Shares Outstanding		787,163
Class B common stock
Document Information Line Items
Entity Common Stock, Shares Outstanding		15,044,547

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Oct. 31, 2020	Jul. 31, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 7,231	$ 6,206
Trade accounts receivable, net of allowance for doubtful accounts of $256 and $218 at October 31, 2020 and July 31, 2020, respectively	309	267
Due from Rafael Pharmaceuticals	240	118
Prepaid expenses and other current assets	460	273
Assets held for sale		2,968
Total current assets	8,240	9,832
Property and equipment, net	44,141	44,433
Equity investment – RP Finance	288	192
Due from RP Finance LLC	1,875
Investments – Rafael Pharmaceuticals	70,018	70,018
Investments – Other Pharmaceuticals	477	1,201
Investments – Hedge Funds	6,454	7,510
Deferred income tax assets, net		6
In-process research and development and patents	1,575	1,575
Other assets	1,550	1,580
TOTAL ASSETS	134,618	136,347
CURRENT LIABILITIES
Trade accounts payable	1,155	921
Accrued expenses	443	1,191
Amount due for purchase of membership interest	3,500	3,500
Other current liabilities	141	115
Due to related parties	30
Total current liabilities	5,269	5,727
Other liabilities	33	92
TOTAL LIABILITIES	5,302	5,819
COMMITMENTS AND CONTINGENCIES
EQUITY
Additional paid-in capital	129,393	129,136
Accumulated deficit	(17,701)	(16,255)
Accumulated other comprehensive income related to foreign currency translation adjustment	3,724	3,762
Total equity attributable to Rafael Holdings, Inc.	115,573	116,800
Noncontrolling interests	13,743	13,728
TOTAL EQUITY	129,316	130,528
TOTAL LIABILITIES AND EQUITY	134,618	136,347
Class A common stock
EQUITY
Common stock value	8	8
TOTAL EQUITY	8	8
Class B common stock
EQUITY
Common stock value	149	149
TOTAL EQUITY	$ 149	$ 149

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Oct. 31, 2020	Jul. 31, 2020
Allowance for doubtful accounts (in Dollars)	$ 256	$ 218
Class A common stock
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	35,000,000	35,000,000
Common stock, shares issued	787,163	787,163
Common stock, shares outstanding	787,163	787,163
Class B common stock
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	15,050,609	15,034,598
Common stock, shares outstanding	15,044,547	15,028,536

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
REVENUE
Rental – Third Party	$ 236	$ 346
Rental – Related Party	520	520
Parking	177	224
Other – Related Party	120	120
Total revenue	1,053	1,210
COSTS AND EXPENSES
Selling, general and administrative	2,592	2,041
Research and development	515	245
Depreciation and amortization	437	466
Loss from operations	(2,491)	(1,542)
Interest expense, net		(64)
Net loss resulting from foreign exchange transactions		(5)
Gain on sale of building	749
Impairment of investments - Other Pharmaceuticals	(724)
Unrealized gain (loss) on investments - Hedge Funds	944	(37)
Loss before income taxes	(1,522)	(1,648)
Provision for income taxes	(5)	(4)
Equity in earnings of RP Finance	96
Consolidated net loss	(1,431)	(1,652)
Net loss (income) attributable to noncontrolling interests	15	(54)
Net loss attributable to Rafael Holdings, Inc.	(1,446)	(1,598)
OTHER COMPREHENSIVE LOSS
Net loss	(1,431)	(1,652)
Foreign currency translation adjustment	(38)	6
Total comprehensive loss	(1,469)	(1,646)
Comprehensive loss attributable to noncontrolling interests	(21)	(2)
Total comprehensive loss attributable to Rafael Holdings, Inc.	$ (1,490)	$ (1,648)
Loss per share
Basic and diluted (in Dollars per share)	$ (0.09)	$ (0.10)
Weighted average number of shares used in calculation of loss per share
Basic and diluted (in Shares)	15,822,722	15,640,683

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands	Total	Additional Paid - in Capital	Accumulated Deficit	Accumulated other comprehensive income	Noncontrolling interests	Common Stock, Series A	Common Stock, Series B
Balance at Jul. 31, 2019	$ 124,764	$ 112,898	$ (5,840)	$ 3,784	$ 13,783	$ 8	$ 131
Balance (in Shares) at Jul. 31, 2019						787,163	13,142,502
Net loss	(1,652)		(1,598)		(54)
Stock-based compensation	94	94
Stock-based compensation (in Shares)							5,000
Shares issued for convertible note	15,668	15,650					$ 18
Shares issued for convertible note (in Shares)							1,849,749
Conversion of LipoMedix bridge notes	82				82
Foreign currency translation adjustment	6			6
Balance at Oct. 31, 2019	138,962	128,642	(7,438)	3,790	13,811	$ 8	$ 149
Balance (in Shares) at Oct. 31, 2019						787,163	14,997,251
Balance at Jul. 31, 2020	130,528	129,136	(16,255)	3,762	13,728	$ 8	$ 149
Balance (in Shares) at Jul. 31, 2020						787,163	15,028,536
Net loss	(1,431)		(1,446)		15
Stock-based compensation	214	214
Stock-based compensation (in Shares)							7,261
Stock options exercised	43	43
Stock options exercised (in Shares)							8,750
Foreign currency translation adjustment	(38)			(38)
Balance at Oct. 31, 2020	$ 129,316	$ 129,393	$ (17,701)	$ 3,724	$ 13,743	$ 8	$ 149
Balance (in Shares) at Oct. 31, 2020						787,163	15,044,547

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Operating activities
Net loss	$ (1,431)	$ (1,652)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	437	466
Deferred income taxes	6	1
Net unrealized (gain) loss on investments - Hedge Funds	(944)	37
Impairment of investments - Other Pharmaceuticals	724
Equity in earnings of RP Finance	(96)
Provision for doubtful accounts	38	48
Stock-based compensation	214	94
Amortization of debt discount		54
Gain on sale of building	(749)
Change in assets and liabilities:
Trade accounts receivable	(80)	173
Prepaid expenses and other current assets	(187)	217
Other assets	30	(289)
Accounts payable and accrued expenses	(490)	(196)
Due from Rafael Pharmaceuticals	(122)
Other current liabilities	26	(12)
Due to related parties	30	(37)
Due from Rafael Pharmaceuticals		160
Other liabilities	(59)
Net cash used in operating activities	(2,653)	(936)
Investing activities
Purchases of property and equipment	(145)	(321)
Payment to fund RP Finance	(1,875)
Proceeds from sale of building	3,658
Proceeds related to distribution of Hedge Funds	2,000
Net cash provided by (used in) investing activities	3,638	(321)
Financing activities
Proceeds from exercise of options	43
Net cash provided by financing activities	43
Effect of exchange rate changes on cash and cash equivalents	(3)	4
Net increase (decrease) in cash and cash equivalents	1,025	(1,253)
Cash and cash equivalents, beginning of period	6,206	12,024
Cash and cash equivalents, end of period	7,231	10,771
Supplemental schedule of noncash investing and financing activities
Conversion of LipoMedix bridge notes		82
Conversions of related party convertible notes payable and accrued interest		$ 15,668

XML 18 R7.htm IDEA: XBRL DOCUMENT

Description of Business

3 Months Ended

Oct. 31, 2020

Accounting Policies [Abstract]

DESCRIPTION OF BUSINESS

NOTE 1 – DESCRIPTION OF BUSINESS

Company	Country of Incorporation	Percentage Owned
Rafael Holdings, Inc.	United States – Delaware		100	%
Broad Atlantic Associates, LLC	United States – Delaware		100	%
IDT 225 Old NB Road, LLC	United States – Delaware		100	%
IDT R.E. Holdings Ltd.	Israel		100	%
Rafael Holdings Realty, Inc.	United States – Delaware		100	%
Barer Institute, Inc.	United States – Delaware		100	%
The Barer Institute, LLC	United States – Delaware		100	%
Hillview Avenue Realty, JV	United States – Delaware		100	%
Hillview Avenue Realty, LLC	United States – Delaware		100	%
Levco Pharmaceuticals Ltd.	Israel		95	%
Farber Partners, LLC	United States – Delaware		93	%
Pharma Holdings, LLC	United States – Delaware		90	%
LipoMedix Pharmaceuticals Ltd.	Israel		68	%
CS Pharma Holdings, LLC	United States – Delaware		45	%*

50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Oct. 31, 2020

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Use of Estimates

Risks and Uncertainties - COVID-19

Investments

Variable Interest Entities

Revenue Recognition

The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due.

Research and Development Costs

Recently Issued Accounting Standards Not Yet Adopted

XML 20 R9.htm IDEA: XBRL DOCUMENT

Investment in Rafael Pharmaceuticals

3 Months Ended

Oct. 31, 2020

Schedule of Investments [Abstract]

INVESTMENT IN RAFAEL PHARMACEUTICALS

NOTE 3 – INVESTMENT IN RAFAEL PHARMACEUTICALS

The Company owns equity interests and rights in Rafael Pharmaceuticals through a 90%-owned non-operating subsidiary, Pharma Holdings, LLC, or Pharma Holdings.

Howard Jonas, Chairman of the Board and Chief Executive Officer of the Company, and Chairman of the Board of Rafael Pharmaceuticals, owns 10% of Pharma Holdings.

Pharma Holdings also holds certain governance rights in Rafael Pharmaceuticals including appointment of directors.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Investment in Altira

3 Months Ended

Oct. 31, 2020

Investment In Acquired Royalty Rights [Abstract]

INVESTMENT IN ALTIRA

NOTE 4 – INVESTMENT IN ALTIRA

XML 22 R11.htm IDEA: XBRL DOCUMENT

Investment in RP Finance, LLC

3 Months Ended

Oct. 31, 2020

Investment In RP Finance LLC [Abstract]

INVESTMENT IN RP FINANCE, LLC

NOTE 5 – INVESTMENT IN RP FINANCE, LLC

XML 23 R12.htm IDEA: XBRL DOCUMENT

Investment in LipoMedix Pharmaceuticals Ltd.

3 Months Ended

Oct. 31, 2020

Business Combinations [Abstract]

INVESTMENT IN LIPOMEDIX PHARMACEUTICALS LTD.

NOTE 6 – INVESTMENT IN LIPOMEDIX PHARMACEUTICALS LTD.

LipoMedix is a development-stage, privately held Israeli company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery.

As of October 31, 2020, the Company held 68% of the issued and outstanding ordinary shares of LipoMedix and has consolidated this investment from the second quarter of fiscal 2018.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Oct. 31, 2020

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 7 – FAIR VALUE MEASUREMENTS

●

Level 1 - quoted prices in active markets for identical assets or liabilities;

●

Level 2 - quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or

●

Level 3 - unobservable inputs for the asset or liability, such as discounted cash flow models or valuations.

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

	Fair value at October 31, 2020
	Level 1		Level 2		Level 3		Total
	*(unaudited, in thousands)*
Assets:
Hedge Funds	$	—	$	—	$	6,454	$	6,454
Total	$	—	$	—	$	6,454	$	6,454

	Fair value at July 31, 2020
	Level 1		Level 2		Level 3		Total
	*(in thousands)*
Assets:
Hedge Funds	$	—	$	—	$	7,510	$	7,510
Total	$	—	$	—	$	7,510	$	7,510

At October 31, 2020 and July 31, 2020, the Company did not have any liabilities measured at fair value on a recurring basis.

The following table summarizes the changes in the fair value of the assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3):

	October 31, 2020			October 31, 2019
	*(unaudited, in thousands)*
Balance, beginning of period	$	7,510		$	5,125
Liquidation of Hedge Fund Investments		(2,000	)		—
Total gain (loss) included in earnings		944			(37	)
Balance, end of period	$	6,454		$	5,088

Fair Value of Other Financial Instruments

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

Trade Accounts Receivable

3 Months Ended

Oct. 31, 2020

Receivables [Abstract]

TRADE ACCOUNTS RECEIVABLE

NOTE 8 – TRADE ACCOUNTS RECEIVABLE

Trade Accounts Receivable consisted of the following:

	October 31, 2020			July 31, 2020
	*(unaudited, in thousands)*			*(in thousands)*
Trade Accounts Receivable	$	415		$	364
Accounts Receivable - Related Party		150			121
Less Allowance for Doubtful Accounts		(256	)		(218	)
Trade Accounts Receivable, net	$	309		$	267

The noncurrent portion of deferred rental income included in Other Assets was approximately $1.5 million as of October 31, 2020 and July 31, 2020.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Property and Equipment

3 Months Ended

Oct. 31, 2020

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 9 – PROPERTY AND EQUIPMENT

Property and equipment consisted of the following:

	October 31, 2020			July 31, 2020
	*(unaudited, in thousands)*			*(in thousands)*
Building and Improvements	$	47,736		$	47,591
Land		10,412			10,412
Furniture and Fixtures		1,145			1,145
Other		256			256
		59,549			59,404
Less Accumulated Depreciation		(15,408	)		(14,971	)
Total	$	44,141		$	44,433

Other property and equipment consist of other equipment and miscellaneous computer hardware.

Depreciation expense pertaining to property and equipment was approximately $0.4 million and $0.5 million for the three months ended October 31, 2020 and 2019, respectively.

The Company’s headquarters are located at 520 Broad Street in Newark, New Jersey where it occupies office space in the building owned by its subsidiary.

In August 2020, the Company sold an office/data center building in Piscataway, New Jersey, which was classified as held for sale at July 31, 2020.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Loss per Share

3 Months Ended

Oct. 31, 2020

Earnings Per Share [Abstract]

LOSS PER SHARE

NOTE 10 – LOSS PER SHARE

	Three months ended October 31,
	2020		2019
Stock Options		571,800		586,874
Total		571,800		586,874

XML 28 R17.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Oct. 31, 2020

RELATED PARTY TRANSACTIONS

NOTE 11 – RELATED PARTY TRANSACTIONS

The Company acquired membership interest in Altira, a related party in fiscal 2020 and fiscal 2021 (see Note 4 and Note 17).

The Company recognized approximately $96 thousand and $0 in income from its ownership interests of 37.5% in RP Finance for the three months ended October 31, 2020 and 2019, respectively (see Note 5).

XML 29 R18.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Oct. 31, 2020

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 12 – INCOME TAXES

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Business Segment Information

3 Months Ended

Oct. 31, 2020

Segment Reporting [Abstract]

BUSINESS SEGMENT INFORMATION

NOTE 13 – BUSINESS SEGMENT INFORMATION

Operating results for the business segments of the Company are as follows:

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Three Months Ended October 31, 2020
Revenues	$	—		$	1,053		$	1,053
Loss from operations		(533	)		(1,958	)		(2,491	)

Three Months Ended October 31, 2019
Revenues	$	—		$	1,210		$	1,210
Loss from operations		(266	)		(1,276	)		(1,542	)

Geographic Information

Three Months Ended October 31, (unaudited)		2020				2019
Revenue from tenants located in Israel			6	%			5	%

Net long-lived assets and total assets held outside of the United States, which are located in Israel, were as follows:

(unaudited, in thousands)	United States		Israel		Total
October 31, 2020
Long-lived assets, net	$	42,564	$	1,577	$	44,141
Total assets		130,744		3,874		134,618

July 31, 2020
Long-lived assets, net	$	42,840	$	1,593	$	44,433
Total assets		132,286		4,061		136,347

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 31 R20.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Oct. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 14 – COMMITMENTS AND CONTINGENCIES

Legal Proceedings

XML 32 R21.htm IDEA: XBRL DOCUMENT

Equity

3 Months Ended

Oct. 31, 2020

Stockholders' Equity Note [Abstract]

EQUITY

NOTE 15 – EQUITY

In August 2019, the note, including interest of approximately $667,000 was converted into 1,849,749 shares of Class B common stock.

During the three months ended October 31, 2020, 8,750 options were exercised. At October 31, 2020, there was no unrecognized compensation cost related to non-vested stock options.

Stock Options

A summary of stock option activity for the Company is as follows:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at July 31, 2020		580,874		$	4.90		2.65	$	2,846
Granted		—			—
Exercised		(8,750	)		4.90
Cancelled / Forfeited		(324	)		—
Outstanding at October 31, 2020		571,800		$	4.90		2.40	$	2,802
Exercisable at October 31, 2020		571,800		$	4.90		2.40	$	2,802

Restricted Stock

A summary of the status of the Company’s grants of restricted shares of Class B common stock is presented below:

	Number of Non-vested Shares			Weighted Average Grant Date Fair Value
Outstanding at July 31, 2020		123,104		$	10.80
Granted		9,360			16.58
Vested		(7,027	)		(16.91	)
Cancelled / Forfeited		(2,099	)		(13.54	)
Non-vested shares at October 31, 2020		123,338		$	13.79

XML 33 R22.htm IDEA: XBRL DOCUMENT

Leases

3 Months Ended

Oct. 31, 2020

Leases [Abstract]

LEASES

NOTE 16 – LEASES

Year ending July 31,	Related Parties		Other		Total
	*(in thousands)*
2021 (remaining)	$	1,532	$	603	$	2,135
2022		2,078		776		2,854
2023		2,117		592		2,709
2024		2,155		538		2,693
2025		1,659		550		2,209
Thereafter		—		1,948		1,948
Total Minimum Future Rental Income	$	9,541	$	5,007	$	14,548

XML 34 R23.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Oct. 31, 2020

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 17 – SUBSEQUENT EVENTS

XML 35 R24.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)	3 Months Ended
Accounting Policies, by Policy (Policies)	Oct. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal 2020 refers to the fiscal year ended July 31, 2020). Operating results for the three months ended October 31, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2021. The balance sheet at July 31, 2020 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2020, or the 2020 Form 10-K, as filed with the U.S. Securities and Exchange Commission (“SEC”).
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates.
Risks and Uncertainties - COVID-19	Risks and Uncertainties - COVID-19 In December 2019, a new coronavirus, now known as COVID-19, which has proved to be highly contagious, emerged in Wuhan, China and has since spread around the globe. The Company actively monitors the outbreak and its potential impact on its operations and those of the Company’s holdings. The impacts on the operations and specifically the ongoing clinical trials of our pharmaceutical holdings have been actively managed by respective pharmaceutical management teams who have worked closely with the appropriate regulatory agencies to continue clinical trial activities with as minimal impact as possible from the pandemic, including receiving waivers for certain clinical trial activities from the respective regulatory agencies to continue the studies. The Company has one tenant that has not paid rent for August 2020 due to the New Jersey state gym closures; however, the tenant subsequently resumed rent payments. There is a general degree of uncertainty in the national commercial real estate market based on the COVID-19 pandemic and as a result there is a potential impact to the value of the Company’s real estate portfolio as well as efforts to monetize those assets. The Company has implemented a number of measures to protect the health and safety of our workforce including a mandatory work-from-home policy for our workforce who can perform their jobs from home as well as restrictions on business travel and workplace and in-person meetings. Due to both known and unknown risks, including quarantines, closures and other restrictions resulting from the outbreak, operations and those of the Company’s holdings may be adversely impacted. Additionally, as there is an evolving nature to the COVID-19 situation, we cannot reasonably assess or predict at this time the full extent of the negative impact that the COVID-19 pandemic may have on our business, financial condition, results of operations and cash flows. The impact will depend on future developments such as the ultimate duration and the severity of the spread of the COVID-19 pandemic in the U.S. and globally, the effectiveness of federal, state, local and foreign government actions on mitigation and spread of COVID-19, the pandemic’s impact on the U.S. and global economies, changes in our customers’ behavior emanating from the pandemic and how quickly we can resume our normal operations, among others. For all these reasons, the Company may incur expenses or delays relating to such events outside of the Company’s control, which could have a material adverse impact on the Company’s business.
Investments	Investments The method of accounting applied to long-term investments, whether consolidated, equity or cost, involves an evaluation of the significant terms of each investment that explicitly grant or suggest evidence of control or influence over the operations of the investee and also includes the identification of any variable interests in which the Company is the primary beneficiary. The consolidated financial statements include the Company’s controlled affiliates. All significant intercompany accounts and transactions between the consolidated affiliates are eliminated. Investments in businesses that the Company does not control, but in which the Company has the ability to exercise significant influence over operating and financial matters, are accounted for using the equity method. Investments in which the Company does not have the ability to exercise significant influence over operating and financial matters are accounted for using the cost method. The Company periodically evaluates its investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded in the accompanying consolidated statements of operations and comprehensive loss, and a new basis in the investment is established.
Variable Interest Entities	Variable Interest Entities In accordance with Accounting Standards Codification (“ASC”) 810, Consolidation, the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities (“VIEs”). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE. If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Cost Method Investments - Rafael Pharmaceuticals (see Note 3) is a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals’ economic performance. Cost method investments are presented as “Investments - Rafael Pharmaceuticals.” Equity Method Investments - RP Finance, LLC (“RP Finance”), (see Note 5), has been identified as a VIE; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of RP Finance that most significantly impact RP Finance’s economic performance and, therefore, is not required to consolidate RP Finance. The Company accounts for its investment in RP Finance using the equity method of accounting.
Revenue Recognition	Revenue Recognition The Company applies the five-step approach as described in ASC 606, Revenue from Contracts with Customers, which consists of the following: (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations in the contract and (v) recognizing revenue when (or as) the entity satisfies a performance obligation. The Company disaggregates its revenue by source within its consolidated statements of operations and comprehensive loss. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing office and parking space to tenants at its properties. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recorded together with rental income on the consolidated statements of operations and comprehensive loss which is also consistent with the guidance under ASC 842, Leases. Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within other assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements. The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company’s performance obligation is satisfied, consistent with the Company’s previous accounting. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due.
Research and Development Costs	Research and Development Costs Research and development costs and expenses incurred by consolidated entities consist primarily of salaries and related personnel expenses, stock-based compensation, fees paid to external service providers, laboratory supplies, costs for facilities and equipment, license costs, and other costs for research and development activities. Research and development expenses are recorded in operating expenses in the period in which they are incurred. Estimates have been used in determining the liability for certain costs where services have been performed but not yet invoiced. The Company monitors levels of performance under each significant contract for external service providers, including the extent of patient enrollment and other activities through communications with the service providers to reflect the actual amount expended. Contingent milestone payments associated with acquiring rights to intellectual property are recognized when probable and estimable. These amounts are expensed to research and development when there is no alternative future use associated with the intellectual property.
Recently Issued Accounting Standards Not Yet Adopted	Recently Issued Accounting Standards Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, that changes the impairment model for most financial assets and certain other instruments. For receivables, loans and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowance for losses. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to current practice, except the losses will be recognized as allowances instead of reductions in the amortized cost of the securities. In addition, an entity will have to disclose significantly more information about allowances, credit quality indicators and past due securities. The new standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and will be applied as a cumulative-effect adjustment to retained earnings. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and intends to adopt the standard on August 1, 2023.

XML 36 R25.htm IDEA: XBRL DOCUMENT

Description of Business (Tables)

3 Months Ended

Oct. 31, 2020

Accounting Policies [Abstract]

Schedule of entities majority-owned subsidiaries

Company	Country of Incorporation	Percentage Owned
Rafael Holdings, Inc.	United States – Delaware		100	%
Broad Atlantic Associates, LLC	United States – Delaware		100	%
IDT 225 Old NB Road, LLC	United States – Delaware		100	%
IDT R.E. Holdings Ltd.	Israel		100	%
Rafael Holdings Realty, Inc.	United States – Delaware		100	%
Barer Institute, Inc.	United States – Delaware		100	%
The Barer Institute, LLC	United States – Delaware		100	%
Hillview Avenue Realty, JV	United States – Delaware		100	%
Hillview Avenue Realty, LLC	United States – Delaware		100	%
Levco Pharmaceuticals Ltd.	Israel		95	%
Farber Partners, LLC	United States – Delaware		93	%
Pharma Holdings, LLC	United States – Delaware		90	%
LipoMedix Pharmaceuticals Ltd.	Israel		68	%
CS Pharma Holdings, LLC	United States – Delaware		45	%*

50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.

XML 37 R26.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Oct. 31, 2020

Fair Value Disclosures [Abstract]

Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy

	Fair value at October 31, 2020
	Level 1		Level 2		Level 3		Total
	*(unaudited, in thousands)*
Assets:
Hedge Funds	$	—	$	—	$	6,454	$	6,454
Total	$	—	$	—	$	6,454	$	6,454

	Fair value at July 31, 2020
	Level 1		Level 2		Level 3		Total
	*(in thousands)*
Assets:
Hedge Funds	$	—	$	—	$	7,510	$	7,510
Total	$	—	$	—	$	7,510	$	7,510

Schedule of assets measured at fair value on a recurring basis using significant unobservable inputs

	October 31, 2020			October 31, 2019
	*(unaudited, in thousands)*
Balance, beginning of period	$	7,510		$	5,125
Liquidation of Hedge Fund Investments		(2,000	)		—
Total gain (loss) included in earnings		944			(37	)
Balance, end of period	$	6,454		$	5,088

XML 38 R27.htm IDEA: XBRL DOCUMENT

Trade Accounts Receivable (Tables)

3 Months Ended

Oct. 31, 2020

Receivables [Abstract]

Schedule of trade accounts receivable

	October 31, 2020			July 31, 2020
	*(unaudited, in thousands)*			*(in thousands)*
Trade Accounts Receivable	$	415		$	364
Accounts Receivable - Related Party		150			121
Less Allowance for Doubtful Accounts		(256	)		(218	)
Trade Accounts Receivable, net	$	309		$	267

XML 39 R28.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

3 Months Ended

Oct. 31, 2020

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

	October 31, 2020			July 31, 2020
	*(unaudited, in thousands)*			*(in thousands)*
Building and Improvements	$	47,736		$	47,591
Land		10,412			10,412
Furniture and Fixtures		1,145			1,145
Other		256			256
		59,549			59,404
Less Accumulated Depreciation		(15,408	)		(14,971	)
Total	$	44,141		$	44,433

XML 40 R29.htm IDEA: XBRL DOCUMENT

Loss per Share (Tables)

3 Months Ended

Oct. 31, 2020

Earnings Per Share [Abstract]

Schedule of earning per share

	Three months ended October 31,
	2020		2019
Stock Options		571,800		586,874
Total		571,800		586,874

XML 41 R30.htm IDEA: XBRL DOCUMENT

Business Segment Information (Tables)

3 Months Ended

Oct. 31, 2020

Segment Reporting [Abstract]

Schedule of operating results for the business segments

(unaudited, in thousands)	Pharmaceuticals			Real Estate			Total
Three Months Ended October 31, 2020
Revenues	$	—		$	1,053		$	1,053
Loss from operations		(533	)		(1,958	)		(2,491	)

Three Months Ended October 31, 2019
Revenues	$	—		$	1,210		$	1,210
Loss from operations		(266	)		(1,276	)		(1,542	)

Schedule of revenue from tenants by geographic areas

Three Months Ended October 31, (unaudited)		2020				2019
Revenue from tenants located in Israel			6	%			5	%

Schedule of net long-lived assets and total assets by geographic areas

(unaudited, in thousands)	United States		Israel		Total
October 31, 2020
Long-lived assets, net	$	42,564	$	1,577	$	44,141
Total assets		130,744		3,874		134,618

July 31, 2020
Long-lived assets, net	$	42,840	$	1,593	$	44,433
Total assets		132,286		4,061		136,347

XML 42 R31.htm IDEA: XBRL DOCUMENT

Equity (Tables)

3 Months Ended

Oct. 31, 2020

Stockholders' Equity Note [Abstract]

Schedule of stock option activity

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at July 31, 2020		580,874		$	4.90		2.65	$	2,846
Granted		—			—
Exercised		(8,750	)		4.90
Cancelled / Forfeited		(324	)		—
Outstanding at October 31, 2020		571,800		$	4.90		2.40	$	2,802
Exercisable at October 31, 2020		571,800		$	4.90		2.40	$	2,802

Schedule of grants of restricted shares of Class B common stock

	Number of Non-vested Shares			Weighted Average Grant Date Fair Value
Outstanding at July 31, 2020		123,104		$	10.80
Granted		9,360			16.58
Vested		(7,027	)		(16.91	)
Cancelled / Forfeited		(2,099	)		(13.54	)
Non-vested shares at October 31, 2020		123,338		$	13.79

XML 43 R32.htm IDEA: XBRL DOCUMENT

Leases (Tables)

3 Months Ended

Oct. 31, 2020

Leases [Abstract]

Schedule of future contractual minimum lease payments

Year ending July 31,	Related Parties		Other		Total
	*(in thousands)*
2021 (remaining)	$	1,532	$	603	$	2,135
2022		2,078		776		2,854
2023		2,117		592		2,709
2024		2,155		538		2,693
2025		1,659		550		2,209
Thereafter		—		1,948		1,948
Total Minimum Future Rental Income	$	9,541	$	5,007	$	14,548

XML 44 R33.htm IDEA: XBRL DOCUMENT

Description of Business (Details)	3 Months Ended
Description of Business (Details)	Oct. 31, 2020
Description of Business (Details) [Line Items]
Percentage owned	50.00%
Interest percentage	45.00%
Pharma Holdings, LLC [Member]
Description of Business (Details) [Line Items]
Percentage owned	90.00%

XML 45 R34.htm IDEA: XBRL DOCUMENT

Description of Business (Details) - Schedule of entities majority-owned subsidiaries

3 Months Ended

Oct. 31, 2020

Rafael Holdings, Inc. [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

United States - Delaware

Percentage Owned

100.00%

Broad Atlantic Associates, LLC [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

United States - Delaware

Percentage Owned

100.00%

IDT 225 Old NB Road, LLC [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

United States - Delaware

Percentage Owned

100.00%

IDT R.E. Holdings Ltd. [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

Israel

Percentage Owned

100.00%

Rafael Holdings Realty, Inc. [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

United States - Delaware

Percentage Owned

100.00%

Barer Institute, Inc. [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

United States - Delaware

Percentage Owned

100.00%

The Barer Institute, LLC [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

United States - Delaware

Percentage Owned

100.00%

Hillview Avenue Realty, JV [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

United States - Delaware

Percentage Owned

100.00%

Hillview Avenue Realty, LLC [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

United States - Delaware

Percentage Owned

100.00%

Levco Pharmaceuticals Ltd. [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

Israel

Percentage Owned

95.00%

Farber Partners, LLC [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

United States - Delaware

Percentage Owned

93.00%

Pharma Holdings, LLC [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

United States - Delaware

Percentage Owned

90.00%

LipoMedix Pharmaceuticals Ltd. [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

Israel

Percentage Owned

68.00%

CS Pharma Holdings, LLC [Member]

Description of Business (Details) - Schedule of entities majority-owned subsidiaries [Line Items]

Country of Incorporation

United States - Delaware

Percentage Owned

45.00%

^[1]

[1]	50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.

XML 46 R35.htm IDEA: XBRL DOCUMENT

Investment in Rafael Pharmaceuticals (Details) - USD ($) shares in Millions, $ in Millions	1 Months Ended	3 Months Ended
	Jan. 31, 2019	Oct. 31, 2020
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Ownership percentage in non-operating subsidiary		50.00%
Fully diluted		10.00%
Principal amount (in Dollars)	$ 10
Convertible promissory note, rate of interest	3.50%
Rafael Pharmaceuticals [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Ownership percentage in non-operating subsidiary		90.00%
Pharma Holdings [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Ownership percentage in non-operating subsidiary		90.00%
Howard Jonas [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Fully diluted		10.00%
Howard Jonas [Member] \| Rafael Pharmaceuticals [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Fully diluted		10.00%
Series D Convertible Preferred Stock [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Exercise of warrants purchases, description		The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution or winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class.
Rafael Pharmaceuticals [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Ownership percentage in subsidiary and holds percentage of interest		50.00%
Indirect interest in assets held, percentage		45.00%
Percentage of outstanding capital stock		51.00%
Percentage of outstanding capital stock on fully diluted basis		37.00%
CS Pharma Holdings, LLC [Member] \| Series D Convertible Preferred Stock [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Exercise price of warrants or rights, description		Pharma Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase ownership to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share
Purchase of exercise the warrant, shares (in Shares)		16.7
Pharma Holdings [Member]
Investment in Rafael Pharmaceuticals (Details) [Line Items]
Exercise price of warrants or rights, description		the Company owned 51% of the issued and outstanding equity in Rafael Pharmaceuticals. At that date, approximately 8% of the issued and outstanding equity was owned by the Company’s subsidiary CS Pharma and 42% was held by the Company’s subsidiary Pharma Holdings. The Company’s subsidiary Pharma Holdings holds a non-dilutive option to increase the Company’s total ownership to 56%. Based on the shares issued and outstanding of Rafael Pharmaceuticals as of October 31, 2020, the Company, and the Company’s affiliates, would need to pay approximately $16 million to exercise the Warrant in full. On an as-converted fully diluted basis (for all convertible securities of Rafael Pharmaceuticals outstanding), the Company, and the Company’s affiliates would need to pay approximately $104 million to exercise the Warrant in full. including additional issuances under the Line of Credit. Howard Jonas holds 10% of the interest in Pharma Holdings and would need to contribute 10% of any cash necessary to exercise any additional portion of the Warrant.

XML 47 R36.htm IDEA: XBRL DOCUMENT

Investment in Altira (Details) - USD ($)		3 Months Ended		12 Months Ended
Investment in Altira (Details) - USD ($)	May 13, 2020	Oct. 31, 2020	Oct. 31, 2019	Jul. 31, 2020
Investment in Altira (Details) [Line Items]
Impairment charge		$ 724,000
Due to the seller		$ 3,500,000
Altira [Member]
Investment in Altira (Details) [Line Items]
Percentage of membership interest		33.333%
Cost of investments		$ 4,000,000
Contingent consideration		$ 6,000,000
Impairment charge				$ 4,000,000
Purchase Agreement [Member]
Investment in Altira (Details) [Line Items]
Purchase agreement, description	the Seller sold the economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive a 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceutical) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the membership interest consists of 1) $1,000,000 payable monthly in four equal installments of $250,000 each; 2) $3,000,000 due on January 3, 2021; 3) $3,000,000 due within fifteen (15) days of interim data analysis in Rafael Pharmaceuticals’ Phase 3 pivotal trial (AVENGER 500®) of CPI-613® (devimistat); and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement. The post-closing payments are to be made, at the Company’s discretion, in cash or shares of the Company’s Class B common stock based on the ten days average share price of the Company’s Class B common stock prior to the date of payment or any combination thereof.

XML 48 R37.htm IDEA: XBRL DOCUMENT

Investment in RP Finance, LLC (Details) - USD ($)		1 Months Ended	3 Months Ended
Investment in RP Finance, LLC (Details) - USD ($)	Feb. 03, 2020	Aug. 31, 2020	Oct. 31, 2020	Oct. 31, 2019	Sep. 30, 2020
Investment in RP Finance, LLC (Details) [Line Items]
Income from interest			$ 96,000	$ 0
Percentage of ownership interest			37.50%	37.50%
Line of Credit Facility, Description		Rafael Pharmaceuticals called for a $5,000,000 draw on the line of credit facility
Capital fund invested			$ 1,875,000
Rafael Pharmaceuticals [Member]
Investment in RP Finance, LLC (Details) [Line Items]
Amount of revolving commitment to funds		$ 5,000,000			$ 5,000,000
Percentage of issued and outstanding shares			12.00%
Line of Credit Agreement [Member]
Investment in RP Finance, LLC (Details) [Line Items]
Amount of revolving commitment to funds	$ 50,000,000
Description line of credit facility	The Company owns 37.5% of the equity interests in RP Finance and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. Howard Jonas owns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. The remaining 25% equity interests in RP Finance is owned by other shareholders of Rafael Pharmaceuticals.

XML 49 R38.htm IDEA: XBRL DOCUMENT

Investment in LipoMedix Pharmaceuticals Ltd. (Details) - USD ($)		1 Months Ended
	Mar. 27, 2020	Oct. 31, 2020	May 20, 2020	Jan. 21, 2020	Mar. 31, 2020	Jan. 31, 2020	Nov. 30, 2019	Nov. 13, 2019
Investment in LipoMedix Pharmaceuticals Ltd. (Details) [Line Items]
Issued and outstanding ordinary shares, percentage		68.00%
Bridge finance					$ 75,000	$ 125,000	$ 100,000
Ordinary shares (in Shares)			4,000,000
Purchase price			$ 1,000,000
Total principal amount								$ 300,000
Interest, for an aggregate amount	$ 693,263			$ 306,737
Minimum [Member] \| LipoMedix [Member]
Investment in LipoMedix Pharmaceuticals Ltd. (Details) [Line Items]
Ownership percentage			58.00%
Maximum [Member] \| LipoMedix [Member]
Investment in LipoMedix Pharmaceuticals Ltd. (Details) [Line Items]
Ownership percentage			68.00%

XML 50 R39.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($)	3 Months Ended
Fair Value Measurements (Details) - USD ($)	Oct. 31, 2020	Oct. 31, 2019
Fair Value Disclosures [Abstract]
Spin-Off, IDT contribution investment amount	$ 2,000,000
Investments in securities	2,000,000
Unrealized loss	$ 700,000	$ 0

XML 51 R40.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy - USD ($) $ in Thousands	Oct. 31, 2020	Jul. 31, 2020
Fair Value Measurements (Details) - Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy [Line Items]
Hedge Funds	$ 6,454	$ 7,510
Total	6,454	7,510
Level 1 [Member]
Fair Value Measurements (Details) - Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy [Line Items]
Hedge Funds
Total
Level 2 [Member]
Fair Value Measurements (Details) - Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy [Line Items]
Hedge Funds
Total
Level 3 [Member]
Fair Value Measurements (Details) - Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy [Line Items]
Hedge Funds	6,454	7,510
Total	$ 6,454	$ 7,510

XML 52 R41.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - Schedule of assets measured at fair value on a recurring basis using significant unobservable inputs - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Balance, beginning of period	$ 7,510	$ 5,125
Liquidation of Hedge Fund Investments	(2,000)
Total gain (loss) included in earnings	944	(37)
Balance, end of period	$ 6,454	$ 5,088

XML 53 R42.htm IDEA: XBRL DOCUMENT

Trade Accounts Receivable (Details) - USD ($) $ in Thousands	Oct. 31, 2020	Jul. 31, 2020
Current Portion of Deferred Rental Income [Member]
Trade Accounts Receivable (Details) [Line Items]
Prepaid expenses and other current assets	$ 77	$ 11
Noncurrent Portion of Deferred Rental Income [Member]
Trade Accounts Receivable (Details) [Line Items]
Other assets	$ 1,500	$ 1,500

XML 54 R43.htm IDEA: XBRL DOCUMENT

Trade Accounts Receivable (Details) - Schedule of trade accounts receivable - USD ($) $ in Thousands	Oct. 31, 2020	Jul. 31, 2020
Schedule of trade accounts receivable [Abstract]
Trade Accounts Receivable	$ 415	$ 364
Accounts Receivable - Related Party	150	121
Less Allowance for Doubtful Accounts	(256)	(218)
Trade Accounts Receivable, net	$ 309	$ 267

XML 55 R44.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($) $ in Millions	3 Months Ended
Property and Equipment (Details) - USD ($) $ in Millions	Oct. 31, 2020	Oct. 31, 2019
Property and Equipment [Member]
Property and Equipment (Details) [Line Items]
Depreciation expense	$ 0.4	$ 0.5

XML 56 R45.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - Schedule of property and equipment - Property and Equipment [Member] - USD ($) $ in Thousands	Oct. 31, 2020	Jul. 31, 2020
Property, Plant and Equipment [Line Items]
Building and Improvements	$ 47,736	$ 47,591
Land	10,412	10,412
Furniture and Fixtures	1,145	1,145
Other	256	256
Property and equipment, gross	59,549	59,404
Less Accumulated Depreciation	(15,408)	(14,971)
Total	$ 44,141	$ 44,433

XML 57 R46.htm IDEA: XBRL DOCUMENT

Loss per Share (Details) - Schedule of earning per share - shares	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Schedule of earning per share [Abstract]
Stock Options	571,800	586,874
Total	571,800	586,874

XML 58 R47.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details)				1 Months Ended			3 Months Ended
Related Party Transactions (Details)	Jan. 10, 2019 USD ($) shares	Nov. 15, 2018	Nov. 05, 2018 USD ($) shares	Jan. 29, 2020 USD ($) shares	Jan. 23, 2019 USD ($) shares	Sep. 30, 2018	Oct. 31, 2020 USD ($) m²	Oct. 31, 2019 USD ($)	Jul. 31, 2020 USD ($)
Related Party Transactions (Details) [Line Items]
Area of land (in Square Meters) \| m²							3,600
Office rent and parking							$ 459,000	$ 459,000
Percentage of total revenue							56.00%	43.00%
Ownership percentage, description							The Company recognized approximately $96 thousand and $0 in income from its ownership interests of 37.5% in RP Finance for the three months ended October 31, 2020 and 2019, respectively (see Note 5).
Related party transaction, description		the Company for $15.0 million convertible into shares of Class B common stock at $8.47 per share. The term of the note was three years with interest on the principal amount at a rate of 6% per annum, compounded quarterly. At issuance, the Company recorded a debt discount of approximately $70,000 related to the beneficial conversion feature of the note and amortized approximately $16,000 of the discount in fiscal 2020 which was recorded as interest expense. In addition, the Company recorded approximately $650,000 of interest expense for the three months ended October 31, 2020 and 2019. In August 2019, the note including accrued interest of approximately $667,000 was converted into 1,849,749 shares of common stock.
IDT Rafael Holdings, LLC [Member]
Related Party Transactions (Details) [Line Items]
Area of land (in Square Meters) \| m²							80,000
IDT [Member]
Related Party Transactions (Details) [Line Items]
Related party expenses							$ 66,000
Due to related parties							30,000
Office rent and parking							69,000	$ 0
Rafael Pharmaceuticals [Member]
Related Party Transactions (Details) [Line Items]
Due from related parties							120,000	$ 120,000
Due from related parties							$ 240,000		$ 120,000
IDT Rafael Holdings, LLC [Member]
Related Party Transactions (Details) [Line Items]
Warrant exercised (in Shares) \| shares	5,100,000		4,000,000		36,300,000
Proceeds from warrant exercises	$ 6,400,000		$ 5,000,000		$ 34,400,000
Howard S. Jonas [Member]
Related Party Transactions (Details) [Line Items]
Due to related parties	$ 640,000		$ 500,000		$ 3,400,000
Class B Common Stock [Member] \| Officer's [Member]
Related Party Transactions (Details) [Line Items]
Restricted shares vested (in Shares) \| shares				5,238
Payroll Taxes				$ 116,000
Cs Pharma Holdings [Member]
Related Party Transactions (Details) [Line Items]
Ownership percentage, description						In September 2018, CS Pharma, in which the Company owns an effective 45% interest, exercised a warrant to purchase 8 million shares of Rafael Pharmaceuticals’ Series D Convertible Preferred Stock for $10 million representing approximately 8% of the equity on a fully-diluted basis (excluding the remainder of the Warrant) of Rafael Pharmaceuticals. The Warrant in full is exercisable for up to 56% of the fully diluted equity of Rafael Pharmaceuticals. The right to exercise the first $10 million of the Warrant was held by CS Pharma. CS Pharma is owned by 0.25% by Michael Weiss, a non-employee director of the Company. The remainder of the Warrant is held by Pharma Holdings.

XML 59 R48.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) $ in Millions	3 Months Ended
Income Taxes (Details) $ in Millions	Oct. 31, 2020 USD ($)
Income Tax Disclosure [Abstract]
Carryforwards of domestic operations	$ 34.4
State of operations	15.3
Foreign of operations	$ 2.3
Taxable income	80.00%

XML 60 R49.htm IDEA: XBRL DOCUMENT

Business Segment Information (Details)	1 Months Ended	12 Months Ended
Business Segment Information (Details)	Aug. 31, 2020	Jul. 31, 2020
Segment Reporting [Abstract]
Number of operating segments		2
Sale of building, description	the Company sold a 3-story, 65,253 square foot office building located at 225 Old New Brunswick Road in Piscataway, New Jersey to 225 ONBR, LLC, an entity unaffiliated with the Company. The purchase price was $3,875,000 and, after transfer taxes and broker’s commission, the Company received $3,675,638 in cash.

XML 61 R50.htm IDEA: XBRL DOCUMENT

Business Segment Information (Details) - Schedule of operating results for the business segments - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Segment Reporting Information [Line Items]
Revenues	$ 1,053	$ 1,210
Loss from operations	(2,491)	(1,542)
Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Revenues
Loss from operations	(533)	(266)
Real Estate [Member]
Segment Reporting Information [Line Items]
Revenues	1,053	1,210
Loss from operations	$ (1,958)	$ (1,276)

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

XML 62 R51.htm IDEA: XBRL DOCUMENT

Business Segment Information (Details) - Schedule of revenue from tenants by geographic areas	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Segment Reporting Information [Line Items]
Revenue from tenants located in Israel	6.00%	5.00%

XML 63 R52.htm IDEA: XBRL DOCUMENT

Business Segment Information (Details) - Schedule of net long-lived assets and total assets by geographic areas - USD ($) $ in Thousands	Oct. 31, 2020	Jul. 31, 2020
Segment Reporting Information [Line Items]
Total assets	$ 134,618	$ 136,347
Business Segment [Member]
Segment Reporting Information [Line Items]
Long-lived assets, net	44,141	44,433
Total assets	134,618	136,347
United States [Member]
Segment Reporting Information [Line Items]
Long-lived assets, net	42,564	42,840
Total assets	130,744	132,286
Israel [Member]
Segment Reporting Information [Line Items]
Long-lived assets, net	1,577	1,593
Total assets	$ 3,874	$ 4,061

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

+ Details

XML 64 R53.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - USD ($)	1 Months Ended	3 Months Ended
Commitments and Contingencies (Details) - USD ($)	Sep. 17, 2018	Oct. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Payment of consulting fees	$ 377,000
Settlement agreement, description		As part of the Settlement Agreement, the Company agreed to pay a penalty of $127,294 in eight quarterly installment payments through November 2021.
Legal fees		$ 64,000

XML 65 R54.htm IDEA: XBRL DOCUMENT

Equity (Details)	1 Months Ended		3 Months Ended
Equity (Details)	Aug. 31, 2019 USD ($)	Nov. 15, 2018 USD ($) $ / shares	Oct. 31, 2020 USD ($) shares
Equity (Details) [Line Items]
Note term		3 years
Interest rate		6.00%
Number of options exercised (in Shares) \| shares			8,750
Unrecognized compensation cost over next period			2 years 65 days
Total unrecognized compensation cost			$ 1,400,000
Restricted Stock [Member]
Equity (Details) [Line Items]
Unrecognized compensation cost over next period			3 years
2018 Equity Incentive Plan [Member]
Equity (Details) [Line Items]
Number of non-employee directors			3
Restricted shares granted (in Shares) \| shares			4,203
Fair value of grants			$ 208,000
Class B Common Stock [Member]
Equity (Details) [Line Items]
Convertible note	$ 667,000	$ 15,000,000
Conversion of common stock price per share (in Dollars per share) \| $ / shares		$ 8.47
Convertible into shares of common stock	1,849,749

XML 66 R55.htm IDEA: XBRL DOCUMENT

Equity (Details) - Schedule of stock option activity $ / shares in Units, $ in Thousands	3 Months Ended
	Oct. 31, 2020 USD ($) $ / shares shares
Schedule of stock option activity [Abstract]
Number of Options, Outstanding, Beginning balance \| shares	580,874
Weighted Average Exercise Price, Outstanding, Beginning balance \| $ / shares	$ 4.90
Weighted Average Remaining Contractual Term (in years), Outstanding, Beginning	2 years 237 days
Aggregate Intrinsic Value, Outstanding, Beginning balance \| $	$ 2,846
Number of Options, Granted \| shares
Weighted Average Exercise Price, Granted \| $ / shares
Number of Options, Exercised \| shares	(8,750)
Weighted Average Exercise Price, Exercised \| $ / shares	$ 4.90
Number of Options, Cancelled / Forfeited \| shares	(324)
Weighted Average Exercise Price, Cancelled / Forfeited \| $ / shares
Number of Options, Outstanding, Ending balance \| shares	571,800
Weighted Average Exercise Price, Outstanding, Ending balance \| $ / shares	$ 4.90
Weighted Average Remaining Contractual Term (in years), Outstanding, Ending balance	2 years 146 days
Aggregate Intrinsic Value, Outstanding, Ending balance \| $	$ 2,802
Number of Options, Exercisable \| shares	571,800
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 4.90
Weighted Average Remaining Contractual Term (in years) Exercisable	2 years 146 days
Aggregate Intrinsic Value, Outstanding, Exercisable \| $	$ 2,802

XML 67 R56.htm IDEA: XBRL DOCUMENT

Equity (Details) - Schedule of grants of restricted shares of Class B common stock	3 Months Ended
	Oct. 31, 2020 $ / shares shares
Schedule of grants of restricted shares of Class B common stock [Abstract]
Number of Non-vested Shares, Beginning Balance \| shares	123,104
Weighted Average Grant Date Fair Value, Beginning balance \| $ / shares	$ 10.80
Number of Non-vested Shares, Granted \| shares	9,360
Weighted Average Grant Date Fair Value, Granted \| $ / shares	$ 16.58
Number of Non-vested Shares, Vested \| shares	(7,027)
Weighted Average Grant Date Fair Value, Vested \| $ / shares	$ (16.91)
Number of Non-vested Shares, Cancelled / Forfeited \| shares	(2,099)
Weighted Average Grant Date Fair Value, Cancelled / Forfeited \| $ / shares	$ (13.54)
Number of Non-vested Shares, Ending Balance \| shares	123,338
Weighted Average Grant Date Fair Value, Ending balance \| $ / shares	$ 13.79

XML 68 R57.htm IDEA: XBRL DOCUMENT

Leases (Details) - USD ($) $ in Thousands	3 Months Ended
Leases (Details) - USD ($) $ in Thousands	Oct. 31, 2020	Oct. 31, 2019
Disclosure Text Block [Abstract]
Net operating leases with initial term expiration dates	The Company is the lessor of certain properties which are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2029.
Other income	$ 634	$ 866
Related party leases expire, description	The Company has related party leases that expire in April 2025 for (i) an aggregate of 88,631 square feet, which includes two parking spots per thousand square feet of space leased at 520 Broad Street, Newark, New Jersey, and (ii) 3,595 square feet in Israel.
Annual rent	$ 2,000
Related parties terminate leases, description	The related parties have the right to terminate the domestic leases upon four months’ notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months’ notice. IDT has the right to lease an additional 50,000 square feet, in 25,000-foot increments, in the building located at 520 Broad Street, Newark, New Jersey on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.

XML 69 R58.htm IDEA: XBRL DOCUMENT

Leases (Details) - Schedule of future contractual minimum lease payments	Jul. 31, 2020 USD ($)
Leases (Details) - Schedule of future contractual minimum lease payments [Line Items]
2021 (remaining)	$ 2,135
2022	2,854
2023	2,709
2024	2,693
2025	2,209
Thereafter	1,948
Total Minimum Future Rental Income	14,548
Related Parties [Member]
Leases (Details) - Schedule of future contractual minimum lease payments [Line Items]
2021 (remaining)	1,532
2022	2,078
2023	2,117
2024	2,155
2025	1,659
Total Minimum Future Rental Income	9,541
Other [Member]
Leases (Details) - Schedule of future contractual minimum lease payments [Line Items]
2021 (remaining)	603
2022	776
2023	592
2024	538
2025	550
Thereafter	1,948
Total Minimum Future Rental Income	$ 5,007

XML 70 R59.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD ($)			3 Months Ended
Subsequent Events (Details) - USD ($)	Dec. 10, 2020	Dec. 07, 2020	Oct. 31, 2020
Subsequent Events (Details) [Line Items]
Description of Purchase Agreement Periodic Payments			In November 2020, Rafael Pharmaceuticals called for a $5 million draw on the line of credit facility and the facility was funded by RP Finance in the amount of $5 million. The Company funded $1.875 million of the $5 million draw in accordance with its 37.5% ownership interests in RP Finance.
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Purchase agreement, description		the Seller sold the economic rights related to a 33.333% membership interest in Altira to the Company and in effect the Company purchased the potential right to receive a 1% royalty on Net Sales (as defined in the Royalty Agreement between Altira and Rafael Pharmaceuticals) on sales of certain Rafael Pharmaceuticals’ products. The purchase consideration for the purchase of the membership interest consists of 1) $1,000,000 payable monthly in four equal installments of $250,000 each, commencing on January 4, 2021; 2) $3,000,000 due on January 4, 2021; 3) $3,000,000 due within fifteen (15) days of the earlier to occur of either the completion of Rafael Pharmaceuticals’ Phase III pivotal trial (AVENGER 500®) of CPI-613® (devimistat) or May 31, 2021 and not before January 4, 2021; and 4) $3,000,000 which is due within one-hundred and twenty (120) days from the date that Rafael Pharmaceuticals files a new drug application with the U.S. Food and Drug Administration for approval of devimistat (CPI-613) as a first in-line therapy for pancreatic cancer, as defined in the Purchase Agreement.
Sale of stock (in Shares)		567,437
Stock price per share (in Dollars per share)		$ 22.91
Aggregate purchase price		$ 13,000,000
Percentage of warrants to purchase		20.00%
Warrant exercise price (in Dollars per share)		$ 22.91
Purchase an aggregate of shares (in Shares)		113,487
Purchased of common stock		$ 218,245
Cash consideration		$ 10,000,000
Annual royalty payment	$ 50,000

EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 146 369 1 true 55 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://rafael.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://rafael.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://rafael.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://rafael.com/role/ConsolidatedIncomeStatement Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Equity (Unaudited) Sheet http://rafael.com/role/ShareholdersEquityType2or3 Consolidated Statements of Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://rafael.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Description of Business Sheet http://rafael.com/role/DescriptionofBusiness Description of Business Notes 7 false false R8.htm 007 - Disclosure - Summary of Significant Accounting Policies Sheet http://rafael.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Investment in Rafael Pharmaceuticals Sheet http://rafael.com/role/InvestmentinRafaelPharmaceuticals Investment in Rafael Pharmaceuticals Notes 9 false false R10.htm 009 - Disclosure - Investment in Altira Sheet http://rafael.com/role/InvestmentinAltira Investment in Altira Notes 10 false false R11.htm 010 - Disclosure - Investment in RP Finance, LLC Sheet http://rafael.com/role/InvestmentinRPFinanceLLC Investment in RP Finance, LLC Notes 11 false false R12.htm 011 - Disclosure - Investment in LipoMedix Pharmaceuticals Ltd. Sheet http://rafael.com/role/InvestmentinLipoMedixPharmaceuticalsLtd Investment in LipoMedix Pharmaceuticals Ltd. Notes 12 false false R13.htm 012 - Disclosure - Fair Value Measurements Sheet http://rafael.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 013 - Disclosure - Trade Accounts Receivable Sheet http://rafael.com/role/TradeAccountsReceivable Trade Accounts Receivable Notes 14 false false R15.htm 014 - Disclosure - Property and Equipment Sheet http://rafael.com/role/PropertyandEquipment Property and Equipment Notes 15 false false R16.htm 015 - Disclosure - Loss per Share Sheet http://rafael.com/role/LossperShare Loss per Share Notes 16 false false R17.htm 016 - Disclosure - Related Party Transactions Sheet http://rafael.com/role/RelatedPartyTransactions Related Party Transactions Notes 17 false false R18.htm 017 - Disclosure - Income Taxes Sheet http://rafael.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 018 - Disclosure - Business Segment Information Sheet http://rafael.com/role/BusinessSegmentInformation Business Segment Information Notes 19 false false R20.htm 019 - Disclosure - Commitments and Contingencies Sheet http://rafael.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 20 false false R21.htm 020 - Disclosure - Equity Sheet http://rafael.com/role/Equity Equity Notes 21 false false R22.htm 021 - Disclosure - Leases Sheet http://rafael.com/role/Leases Leases Notes 22 false false R23.htm 022 - Disclosure - Subsequent Events Sheet http://rafael.com/role/SubsequentEvents Subsequent Events Notes 23 false false R24.htm 023 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://rafael.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://rafael.com/role/SummaryofSignificantAccountingPolicies 24 false false R25.htm 024 - Disclosure - Description of Business (Tables) Sheet http://rafael.com/role/DescriptionofBusinessTables Description of Business (Tables) Tables http://rafael.com/role/DescriptionofBusiness 25 false false R26.htm 025 - Disclosure - Fair Value Measurements (Tables) Sheet http://rafael.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://rafael.com/role/FairValueMeasurements 26 false false R27.htm 026 - Disclosure - Trade Accounts Receivable (Tables) Sheet http://rafael.com/role/TradeAccountsReceivableTables Trade Accounts Receivable (Tables) Tables http://rafael.com/role/TradeAccountsReceivable 27 false false R28.htm 027 - Disclosure - Property and Equipment (Tables) Sheet http://rafael.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://rafael.com/role/PropertyandEquipment 28 false false R29.htm 028 - Disclosure - Loss per Share (Tables) Sheet http://rafael.com/role/LossperShareTables Loss per Share (Tables) Tables http://rafael.com/role/LossperShare 29 false false R30.htm 029 - Disclosure - Business Segment Information (Tables) Sheet http://rafael.com/role/BusinessSegmentInformationTables Business Segment Information (Tables) Tables http://rafael.com/role/BusinessSegmentInformation 30 false false R31.htm 030 - Disclosure - Equity (Tables) Sheet http://rafael.com/role/EquityTables Equity (Tables) Tables http://rafael.com/role/Equity 31 false false R32.htm 031 - Disclosure - Leases (Tables) Sheet http://rafael.com/role/LeasesTables Leases (Tables) Tables http://rafael.com/role/Leases 32 false false R33.htm 032 - Disclosure - Description of Business (Details) Sheet http://rafael.com/role/DescriptionofBusinessDetails Description of Business (Details) Details http://rafael.com/role/DescriptionofBusinessTables 33 false false R34.htm 033 - Disclosure - Description of Business (Details) - Schedule of entities majority-owned subsidiaries Sheet http://rafael.com/role/ScheduleofentitiesmajorityownedsubsidiariesTable Description of Business (Details) - Schedule of entities majority-owned subsidiaries Details http://rafael.com/role/DescriptionofBusinessTables 34 false false R35.htm 035 - Disclosure - Investment in Rafael Pharmaceuticals (Details) Sheet http://rafael.com/role/InvestmentinRafaelPharmaceuticalsDetails Investment in Rafael Pharmaceuticals (Details) Details http://rafael.com/role/InvestmentinRafaelPharmaceuticals 35 false false R36.htm 036 - Disclosure - Investment in Altira (Details) Sheet http://rafael.com/role/InvestmentinAltiraDetails Investment in Altira (Details) Details http://rafael.com/role/InvestmentinAltira 36 false false R37.htm 037 - Disclosure - Investment in RP Finance, LLC (Details) Sheet http://rafael.com/role/InvestmentinRPFinanceLLCDetails Investment in RP Finance, LLC (Details) Details http://rafael.com/role/InvestmentinRPFinanceLLC 37 false false R38.htm 038 - Disclosure - Investment in LipoMedix Pharmaceuticals Ltd. (Details) Sheet http://rafael.com/role/InvestmentinLipoMedixPharmaceuticalsLtdDetails Investment in LipoMedix Pharmaceuticals Ltd. (Details) Details http://rafael.com/role/InvestmentinLipoMedixPharmaceuticalsLtd 38 false false R39.htm 039 - Disclosure - Fair Value Measurements (Details) Sheet http://rafael.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://rafael.com/role/FairValueMeasurementsTables 39 false false R40.htm 040 - Disclosure - Fair Value Measurements (Details) - Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy Sheet http://rafael.com/role/ScheduleoffairvalueonarecurringbasisandwheretheyareclassifiedwithinthefairvaluehierarchyTable Fair Value Measurements (Details) - Schedule of fair value on a recurring basis and where they are classified within the fair value hierarchy Details http://rafael.com/role/FairValueMeasurementsTables 40 false false R41.htm 041 - Disclosure - Fair Value Measurements (Details) - Schedule of assets measured at fair value on a recurring basis using significant unobservable inputs Sheet http://rafael.com/role/ScheduleofassetsmeasuredatfairvalueonarecurringbasisusingsignificantunobservableinputsTable Fair Value Measurements (Details) - Schedule of assets measured at fair value on a recurring basis using significant unobservable inputs Details http://rafael.com/role/FairValueMeasurementsTables 41 false false R42.htm 042 - Disclosure - Trade Accounts Receivable (Details) Sheet http://rafael.com/role/TradeAccountsReceivableDetails Trade Accounts Receivable (Details) Details http://rafael.com/role/TradeAccountsReceivableTables 42 false false R43.htm 043 - Disclosure - Trade Accounts Receivable (Details) - Schedule of trade accounts receivable Sheet http://rafael.com/role/ScheduleoftradeaccountsreceivableTable Trade Accounts Receivable (Details) - Schedule of trade accounts receivable Details http://rafael.com/role/TradeAccountsReceivableTables 43 false false R44.htm 044 - Disclosure - Property and Equipment (Details) Sheet http://rafael.com/role/PropertyandEquipmentDetails Property and Equipment (Details) Details http://rafael.com/role/PropertyandEquipmentTables 44 false false R45.htm 045 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment Sheet http://rafael.com/role/ScheduleofpropertyandequipmentTable Property and Equipment (Details) - Schedule of property and equipment Details http://rafael.com/role/PropertyandEquipmentTables 45 false false R46.htm 046 - Disclosure - Loss per Share (Details) - Schedule of earning per share Sheet http://rafael.com/role/ScheduleofearningpershareTable Loss per Share (Details) - Schedule of earning per share Details http://rafael.com/role/LossperShareTables 46 false false R47.htm 047 - Disclosure - Related Party Transactions (Details) Sheet http://rafael.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://rafael.com/role/RelatedPartyTransactions 47 false false R48.htm 048 - Disclosure - Income Taxes (Details) Sheet http://rafael.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://rafael.com/role/IncomeTaxes 48 false false R49.htm 049 - Disclosure - Business Segment Information (Details) Sheet http://rafael.com/role/BusinessSegmentInformationDetails Business Segment Information (Details) Details http://rafael.com/role/BusinessSegmentInformationTables 49 false false R50.htm 050 - Disclosure - Business Segment Information (Details) - Schedule of operating results for the business segments Sheet http://rafael.com/role/ScheduleofoperatingresultsforthebusinesssegmentsTable Business Segment Information (Details) - Schedule of operating results for the business segments Details http://rafael.com/role/BusinessSegmentInformationTables 50 false false R51.htm 051 - Disclosure - Business Segment Information (Details) - Schedule of revenue from tenants by geographic areas Sheet http://rafael.com/role/ScheduleofrevenuefromtenantsbygeographicareasTable Business Segment Information (Details) - Schedule of revenue from tenants by geographic areas Details http://rafael.com/role/BusinessSegmentInformationTables 51 false false R52.htm 052 - Disclosure - Business Segment Information (Details) - Schedule of net long-lived assets and total assets by geographic areas Sheet http://rafael.com/role/ScheduleofnetlonglivedassetsandtotalassetsbygeographicareasTable Business Segment Information (Details) - Schedule of net long-lived assets and total assets by geographic areas Details http://rafael.com/role/BusinessSegmentInformationTables 52 false false R53.htm 053 - Disclosure - Commitments and Contingencies (Details) Sheet http://rafael.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://rafael.com/role/CommitmentsandContingencies 53 false false R54.htm 054 - Disclosure - Equity (Details) Sheet http://rafael.com/role/EquityDetails Equity (Details) Details http://rafael.com/role/EquityTables 54 false false R55.htm 055 - Disclosure - Equity (Details) - Schedule of stock option activity Sheet http://rafael.com/role/ScheduleofstockoptionactivityTable Equity (Details) - Schedule of stock option activity Details http://rafael.com/role/EquityTables 55 false false R56.htm 056 - Disclosure - Equity (Details) - Schedule of grants of restricted shares of Class B common stock Sheet http://rafael.com/role/ScheduleofgrantsofrestrictedsharesofClassBcommonstockTable Equity (Details) - Schedule of grants of restricted shares of Class B common stock Details http://rafael.com/role/EquityTables 56 false false R57.htm 057 - Disclosure - Leases (Details) Sheet http://rafael.com/role/LeasesDetails Leases (Details) Details http://rafael.com/role/LeasesTables 57 false false R58.htm 058 - Disclosure - Leases (Details) - Schedule of future contractual minimum lease payments Sheet http://rafael.com/role/ScheduleoffuturecontractualminimumleasepaymentsTable Leases (Details) - Schedule of future contractual minimum lease payments Details http://rafael.com/role/LeasesTables 58 false false R59.htm 059 - Disclosure - Subsequent Events (Details) Sheet http://rafael.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://rafael.com/role/SubsequentEvents 59 false false All Reports Book All Reports rfl-20201031.xml rfl-20201031.xsd rfl-20201031_cal.xml rfl-20201031_def.xml rfl-20201031_lab.xml rfl-20201031_pre.xml http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 76 0001213900-20-042808-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-20-042808-xbrl.zip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�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